WO1995024929A2 - Polymeric gene delivery system - Google Patents
Polymeric gene delivery system Download PDFInfo
- Publication number
- WO1995024929A2 WO1995024929A2 PCT/US1995/003307 US9503307W WO9524929A2 WO 1995024929 A2 WO1995024929 A2 WO 1995024929A2 US 9503307 W US9503307 W US 9503307W WO 9524929 A2 WO9524929 A2 WO 9524929A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polymer
- gene
- cells
- polymeric
- dna
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Definitions
- the present invention is generally in the area of drug delivery devices and is specifically in the area of polymeric drug delivery devices.
- Gene Therapy is generally defined as the introduction and expression of an exogenous gene in an animal to supplement or replace a defective or missing gene. Examples that have received a great deal of recent attention include the genes missing in cystic fibrosis and severe combined immunodeficiency. Although tremendous progress has been made in the area of gene therapy, obtaining high level and long term expression of the desired proteins remains elusive.
- a retroviral vector is used to introduce the gene to be expressed into appropriate cells. Gene transfer is most commonly achieved through a cell-mediated ex vivo therapy in which cells from the blood or tissue are genetically modified in the laboratory and subsequently returned to the patient.
- the clinical studies by Steven Rosenberg, et al. "Immunotherapy of patients with metastatic melanoma using tumor- infiltrating lymphocytes and IL-2", Preliminary report, New England J ' . Med. , 319 (1988) 1676-1680, using in vi tro- activated LAK and TIL for tumor destruction illustrates this approach.
- the vector carrying the gene to be expressed is introduced into the patient, for example, by inhalation into the lungs in the case of cystic fibrosis.
- Transfected cells have also been implanted, alone or encapsulated within a protective membrane that protects the cells from the inflammatory response of the body while at the same time allowing the gene product to diffuse out of the membrane.
- a protective membrane that protects the cells from the inflammatory response of the body while at the same time allowing the gene product to diffuse out of the membrane.
- Plasmid DNA which can function episomally, has been used with liposome encapsulation, CaP0 4 precipitation and electroporation as an alternative to viral transfections.
- Recent clinical trials with liposome encapsulated DNA in treating melanoma illustrates this approach to gene therapy, as reported by Nabel, J.G., et al. , "Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biological activity and lack of toxicity in humans", Proc . Na t . Acad. Sci . U. S.A . , 90 (1993) 11307-11311.
- a foreign gene coding for HLA-B was introduced into subcutaneous sites of melanoma tumors.
- oligonucleotides which are typically a maximum of twenty to thirty nucleotides in length
- genes encoding most molecules of therapeutic interest are quite large, and therefore considerably more difficult to introduce into cells other than through retroviral vector, or in vi tro, by chemical manipulation, so that the efficiency of transfer is low.
- transient high level expression of up to a few weeks or months has been observed.
- transfections with naked DNA have several advantages over viral transfers. Most importantly, concerns related to the immunogenicity and transforming capability of viruses are avoided.
- naked DNA is easy to produce in large quantities, is inexpensive, and can be injected at high concentration into localized tissue sites allowing gene expression in si tu without extensive ex vivo therapy.
- Gene therapy is one of the most promising areas of research today. It would therefore be extremely useful if one had an efficient way to introduce genes into cells which yielded long term expression.
- a means for obtaining efficient introduction of exogenous genes into a patient, with long term expression of the gene, is disclosed.
- the gene under control of an appropriate promoter for expression in a particular cell type, is encapsulated or dispersed with a biocompatible, preferably biodegradable polymeric matrix, where the gene is able to diffuse out of the matrix over an extended period of time, for example, a period of three to twelve months or longer.
- the matrix is preferably in the form of a microparticle such as a microsphere (where the gene is dispersed throughout a solid polymeric matrix) or microcapsule (gene is stored in the core of a polymeric shell) , although other forms including films, coatings, gels, implants, and stents can also be used.
- the gene, or other DNA or RNA to be delivered can be incorporated directly into the polymer, or first incorporated into another material enhancing penetration of the DNA through the cell wall, such as liposomes or surfactants.
- the size and composition of the polymeric device is selected to result in favorable release kinetics in tissue.
- the size is also selected according to the method of delivery which is to be used, typically injection into a tissue or administration of a suspension by aerosol into the nasal and/or pulmonary areas.
- the matrix composition can be selected to not only have favorable degradation rates, but to be formed of a material which is bioadhesive, to further increase the effectiveness of transfer when administered to a mucosal surface, or selected not to degrade but to release by diffusion over an extended period.
- Gene transfer is achieved using a polymeric delivery system which releases entrapped genes, usually in combination with an appropriate promoter for expression of the gene, into surrounding tissue. Efficacy of transfer is achieved by: a) releasing the gene for prolonged period of time, b) minimizing diffusion of the gene out of the delivery system (due to its size) so that release is predominantly degradation dependent, and c) improving the transient time of expression and the low infection seen by direct gene ⁇ therapy.
- the device is formulated so that the gene is released via diffusion. This is achieved by creating porous systems or adding soluble bulking agents that create pores as they leach out of the system.
- Both non-biodegradable and biodegradable matrices can be used for delivery of genes, although biodegradable matrices are preferred. These may be natural or synthetic polymers, although synthetic polymers are preferred due to the better characterization of degradation and release profiles.
- the polymer is selected based on the period over which release is desired, generally in the range of at least three months to twelve months, although longer periods may be desirable. In some cases linear release may be most useful, although in others a pulse release or "bulk release" may provided more effective results.
- the polymer may be in the form of a hydrogel (typically in absorbing up to about 90% by weight of water) , and can optionally be crosslinked with multivalent ions or polymers.
- High molecular weight genes can be delivered partially by diffusion but mainly by degradation of the polymeric system.
- biodegradable polymers bioerodible hydrogels, and protein delivery systems are particularly preferred.
- Representative synthetic polymers are: polyamides, polycarbonates, polyalkylenes, polyalkylene glycols, polyalkylene oxides, polyalkylene terepthalates, polyvinyl alcohols, polyvinyl ethers, polyvinyl esters, polyvinyl halides, polyvinylpyrrolidone, polyglycolides, polysiloxanes, polyurethanes and co-polymers thereof, alkyl cellulose, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitro celluloses, polymers of acrylic and methacrylic esters, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxy-propyl methyl cellulose, hydroxybutyl methyl cellulose, cellulose acetate, cellulose
- non-biodegradable polymers include ethylene vinyl acetate, poly( eth) acrylic acid, polyamides, copolymers and mixtures thereof.
- biodegradable polymers include synthetic polymers such as polymers of lactic acid and glycolic acid, polyanhydrides, poly(ortho) esters, polyurethanes, poly(butic acid), poly(valeric acid) , and poly(lactide-co- caprolactone) , and natural polymers such as alginate and other polysaccharides including dextran and cellulose, collagen, chemical derivatives thereof (substitutions, additions of chemical groups, for example, alkyl, alkylene, hydroxylations, oxidations, and other modifications routinely made by those skilled in the art) , albumin and other hydrophilic proteins, zein and other prolamines and hydrophobic proteins, copolymers and mixtures thereof. In general, these materials degrade either by enzymatic hydrolysis or exposure to water in vivo, by surface or bulk erosion.
- Bioadhesive polymers of particular interest include bioerodible hydrogels described by H.S. Sawhney, C.P. Pathak and J.A. Hubell in
- polyhyaluronic acids casein, gelatin, glutin, polyanhydrides, polyacrylic acid, alginate, chitosan, poly(methyl methacrylates) , poly(ethyl methacrylates) , poly(butylmethacrylate) , poly(isobutyl methacrylate) , poly(hexylmethacrylate) , poly(isodecyl methacrylate), polydauryl methacrylate) , poly(phenyl methacrylate) , poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), and poly(octadecyl acrylate) .
- the polymeric matrix is a microparticle between nanometers and one millimeter in diameter, more preferably between 0.5 and 100 microns for administration via injection or inhalation (aerosol) .
- microparticles can be microspheres, where gene is dispersed within a solid polymeric matrix, or microcapsules, where the core is of a different material than the polymeric shell, and the gene is dispersed or suspended in the core, which may be liquid or solid in nature.
- the polymer may be cast as a thin slab or film, ranging from nanometers to four centimeters, a powder produced by grinding or other standard techniques, or even a gel such as a hydrogel.
- the polymer can also be in the form of a coating or part of a stent or catheter, vascular graft, or other prosthetic device.
- Methods for Making the Matrix The matrices can be formed by solvent evaporation, spray drying, solvent extraction and other methods known to those skilled in the art. Microsphere Preparation
- Bioerodible microspheres can be prepared using any of the methods developed for making microspheres for drug delivery, for example, as described by Mathiowitz and Langer, J. Controlled Release 5,13-22 (1987) ; Mathiowitz, et al. , Reactive Polymers 6, 275-283 (1987) ; and Mathiowitz, et al. , J. Appl. Polymer Sci. 35, 755- 774 (1988) , the teachings of which are incorporated herein. The selection of the method depends on the polymer selection, the size, external morphology, and crystallinity that is desired, as described, for example, by Mathiowitz, et al.
- the polymer is dissolved in a volatile organic solvent.
- the DNA either in soluble form or dispersed as fine particles, is added to the polymer solution, and the mixture is suspended in an aqueous phase that contains a surface active agent such as poly(vinyl alcohol) .
- The- resulting emulsion is stirred until most of the organic solvent evaporates, leaving solid microspheres.
- the polymer can be dissolved in methylene chloride.
- methylene chloride Several different polymer concentrations can be used, for example, between 0.05 and 0.20 g/ml.
- the solution is suspended in 200 ml of vigorously stirring distilled water containing 1% (w/v) poly(vinyl alcohol) (Sigma Chemical Co., St. Louis, MO) .
- the organic solvent will have evaporated from the polymer, and the resulting microspheres will be washed with water and dried overnight in a lyophilizer.
- Microspheres with different sizes (1-1000 microns) and morphologies can be obtained by this method which is useful for relatively stable polymers such as polyesters and polystyrene.
- relatively stable polymers such as polyesters and polystyrene.
- labile polymers such as polyanhydrides may degrade due to exposure to water.
- hot melt encapsulation and solvent removal may be preferred.
- the polymer In hot melt encapsulation, the polymer is first melted and then mixed with the solid particles of DNA, preferably sieved to less than 50 ⁇ m. The mixture is suspended in a non-miscible solvent such as silicon oil and, with continuous stirring, heated to 5°C above the melting point of the polymer. Once the emulsion is stabilized, it is cooled until the polymer particles solidify. The resulting microspheres are washed by decantation with petroleum ether to give a free- flowing powder. Microspheres with diameters between one and 1000 microns can be obtained with this method. The external surface of spheres prepared with this technique are usually smooth and dense. This procedure is useful with water labile polymers, but is limited to use with polymers with molecular weights between 1000 and 50000.
- Solvent removal was primarily designed for use with polyanhydrides.
- the drug is dispersed or dissolved in a solution of a selected polymer in a volatile organic solvent like methylene chloride.
- the mixture is then suspended in oil, such as silicon oil, by stirring, to form an emulsion.
- oil such as silicon oil
- the solvent diffuses into the oil phase and the emulsion droplets harden into solid polymer microspheres.
- this method can be used to make microspheres from polymers with high melting points and a wide range of molecular weights. Microspheres having a diameter between one and 300 microns can be obtained with this procedure.
- the external morphology of the spheres is highly dependent on the type of polymer used.
- the polymer In spray drying, the polymer is dissolved in methylene chloride (0.04 g/ml) . A known amount of active drug is suspended (if insoluble) or co- dissolved (if soluble) in the polymer solution. The solution or the dispersion is then spray-dried.
- Double walled microspheres can be prepared according to U.S. Patent No. 4,861,627 to Mathiowitz .
- Hydrogel microspheres made of gel-type polymers such as alginate or polyphosphazenes or other dicarboxylic polymers can be prepared by dissolving the polymer in an aqueous solution, suspending the material to be incorporated into the mixture, and extruding the polymer mixture through a microdroplet forming device, equipped with a nitrogen gas jet. The resulting microspheres fall into a slowly stirring, ionic hardening bath, as described, for example, by Salib, et al., Pharmazeutician Industrie 40-11A, 1230 (1978) , the teachings of which are incorporated herein.
- the advantage of this system is the ability to further modify the surface of the microspheres by coating them with polycationic polymers such as polylysine, after fabrication, for example, as described by Lim, et al . , J. Pharm. Sci. 70, 351-354 (1981) .
- polycationic polymers such as polylysine
- a hydrogel can be formed by ionically crosslinking the alginate with calcium ions, then crosslinking the outer surface of the microparticle with a polycation such as polylysine, after fabrication.
- the microsphere particle size will be controlled using various size extruders, polymer flow rates and gas flow rates.
- Chitosan microspheres can be prepared by dissolving the polymer in acidic solution and crosslinking with tripolyphosphate.
- carboxymethylcellulose (CMC) microsphere are prepared by dissolving the polymer in an acid solution and precipitating the microspheres with lead ions.
- Alginate/polyethylene imide (PEI) can be prepared to reduce the amount of carboxyl groups on the alginate microcapsules.
- Table 1 summarizes various hydrogels, concentrations, ionic baths, and stirring rates used to manufacture them. Table 1: Preparation of Hydrogel Matrices Hydrogel Hydrogel dissolving bath ionic bath stirring concen. pH Temp 0 C concen. (w/v) rate(rpm) chitosan 1.0% 5.0 23 3% tripoly- 170 phosphate alginate 2.0% 7.4 50 1.3% calcium 160 chloride alginate/ 2 . 0%/ 7.4 50 1.3% calcium 160
- Other delivery systems including films , coatings, pellets , slabs , and devices can be fabricated using solvent or melt casting, and extrusion, as well as standard methods for making composites .
- the polymer can be produced by first mixing monomers and DNA as described by Sawhney, et al . , and polymerizing the monomers with UV light. The polymerization can be carried out in vi tro as well as in vivo. Thus, any biocompatible glue could be also used to incorporate the DNA. Loading of Gene
- the range of loading of the gene to be delivered is typically between about 0.01% and 90%, depending on the form and size of the gene to be delivered and the target tissue.
- a "gene” is an isolated nucleic acid molecule of greater than thirty nucleotides, preferably one hundred nucleotides or more, in length.
- genes which replace or supplement function include the genes encoding missing enzymes such as adenosine deaminase (ADA) which has been used in clinical trials to treat ADA deficiency and cofactors such as insulin and coagulation factor VIII.
- ADA adenosine deaminase
- Genes which effect regulation can also be administered, alone or in combination with a gene supplementing or replacing a specific function.
- a gene encoding a protein which suppresses expression of a particular protein- encoding gene, or vice versa, which induces expresses of a protein-encoding gene can be administered in the matrix.
- genes which are useful in stimulation of the immune response include viral antigens and tumor antigens, as well as cytokines (tumor necrosis factor) and inducers of cytokines
- the chronic immune response to the polymeric matrix is mediated by the action of a variety of growth factors including epidermal growth factor
- EGF platelet-derived growth factor
- FGFs fibroblast growth factors
- TGF- ⁇ and TGF- ⁇ transforming growth factors
- IL- ⁇ interleukin-1
- TNF tumor necrosis factor
- Inhibitors of these inflammatory mediators in combination with a gene to be delivered other than the immune inhibitor would be effective in decreasing the normal inflammatory response directed toward the polymeric matrix. By inhibiting the amount of encapsulation of the matrix, the effective release would be further extended. Examples of materials which could inhibit encapsulation include antisense mRNA to suppress fibrin or collagen formation, inhibitors of EGF, PDGF, FGFs, TGF- ⁇ , TGF- ⁇ , IL-1 and TNF and anti-inflammatory agents such as corticosteroids and cyclosporin.
- Genes can be obtained using literature references or from commercial suppliers. They can be synthesized using solid phase synthesis if relatively small, or obtained in expression vectors, for example, as deposited with the
- vectors are agents that transport the gene into the cell without degradation and include a promoter yielding expression of the gene in the cells into which it is delivered. Promoters can be general promoters, yielding expression in a variety of mammalian cells, or cell specific, or even nuclear versus cytoplasmic specific. These are known to those skilled in the art and can be constructed using standard molecular biology protocols. Although as demonstrated by the examples, the genes will diffuse out of the polymeric matrix into the surrounding cells where they are expressed, in a preferred embodiment, the genes are delivered in combination with a vector to further enhance uptake and expression. Vectors are divided into two classes: a) Biological agents derived from viral, bacterial or other sources. b) Chemical/ physical methods that increase the potential for gene uptake, directly introduce the gene into the nucleus or target the gene to a cell receptor. Biological Vectors
- Retroviral vectors have higher transaction (ability to introduce genes) abilities than do most chemical or physical methods to introduce genes into cells. Retroviral vectors are the vectors most commonly used in clinical trials, since they carry a larger genetic payload than other viral vectors. However, they are not useful in non-proliferating cells.
- Adenovirus vectors are relatively stable and easy to work with, have high titers, and can be delivered in aerosol formulation. However, many people may have pre-existing antibodies negating effectiveness and they are difficult to produce in quantity. Pox viral vectors are large and have several sites for inserting genes, they are thermostable and can be stored at room temperature. However, they cannot be transmitted from host to host and there are some safety issues since they can enter other cells.
- Plasmids are not integrated into the genome and the vast majority of them are present only from a few weeks to several months, so they are typically very safe. However, they have lower expression levels than retroviruses and since cells have the ability to identify and eventually shut down foreign gene expression, the continuous release of DNA from the polymer to the target cells substantially increases the duration of functional expression while maintaining the benefit of the safety associated with non-viral transfections.
- Chemical/physical vectors are not integrated into the genome and the vast majority of them are present only from a few weeks to several months, so they are typically very safe. However, they have lower expression levels than retroviruses and since cells have the ability to identify and eventually shut down foreign gene expression, the continuous release of DNA from the polymer to the target cells substantially increases the duration of functional expression while maintaining the benefit of the safety associated with non-viral transfections.
- nucleic acid molecules into liposomes or complexed to liposomes which are then entrapped or otherwise incorporated into the polymeric matrix for delivery to cells.
- the ratio of liposome to polymer solution is important in determining whether the liposomes will remain as separate entities during the process for incorporation into the polymeric matrix. If the ratio of solvent is too high, the phospholipid will dissolve into the polymer solvent, rather than remaining as part of the liposome bilayer. This is a function of the liposome composition, polymer concentration, and solvent composition. The liposomes increase the efficiency of the transfer of the DNA into the cells.
- Liposomes are commercially available from Gibco BRL, for example, as LIPOFECTIN ® and LIPOFECTACE ® , which are formed of cationic lipids such as N-[l-(2,3 dioleyloxy) -propyl] -n,n,n- trimethylammonium chloride (DOTMA) and dimethyl dioctadecylammonium bromide (DDAB) . Numerous methods are also published for making liposomes, known to those skilled in the art.
- LIPOFECTIN ® and LIPOFECTACE ® are formed of cationic lipids such as N-[l-(2,3 dioleyloxy) -propyl] -n,n,n- trimethylammonium chloride (DOTMA) and dimethyl dioctadecylammonium bromide (DDAB) .
- DOTMA N-[l-(2,3 dioleyloxy) -propyl] -n,n,n
- any nucleic acid molecule including genes as defined above, antisense, ribozymes and ribozyme targeting molecules, and probes, defined as an oligonucleotide of at least fourteen to seventeen nucleotides in length, can be mixed with, or incorporated into, the liposomes.
- the liposome- nucleic acid molecule mixture is then mixed with a polymer solution.
- the polymer solution can be formed by melting of a polymer, dissolution of a polymer in a solvent, or selection of a polymer that is a liquid under certain conditions, such as an acidic pH or room temperature, which is then solidified by a change in conditions.
- the microparticles can be suspended in any appropriate pharmaceutical carrier, such as saline, for administration to a patient.
- saline a pharmaceutical carrier
- the microparticles will be stored in dry or lyophilized form until immediately before administration. They will then be suspended in sufficient solution for administration.
- microparticles in combination with an adjuvant to enhance the inflammatory response against the polymer and thereby increase the likelihood of phagocytosis by macrophages and other hematopoietic cells, with subsequent expression of the gene specifically within these cells, or, in the case where the microparticles contain an anti- cancer agent, to enhance the inflammatory reaction against the tumor cells in combination with the effect of the anti-cancer agent.
- the polymeric microparticles can be administered by injection, infusion, implantation, orally (not preferred) , or administration to a mucosal surface, for example, the nasal-pharyngeal region and/or lungs using an aerosol, or in a cream, ointment, spray, or other topical carrier, for example, to rectal or vaginal areas.
- slabs, coatings, rods, and other devices are preferably administered by implantation in the area where release is desired.
- the materials can also be incorporated into an appropriate vehicle for transdermal delivery as well as stents.
- Appropriate vehicles include ointments, lotions, patches, and other standard delivery means. Targeting of cell populations through polymer material characteristics.
- biodegrading polymers can be used to target inflammatory cells due to the inability of the plasmid DNA (pDNA) to migrate across the reactive tissue layer to the site specific tissue.
- pDNA plasmid DNA
- a more biocompatible material which induces a weaker response from the host will result in a thinner layer of inflammatory cells, enabling the released pDNA to migrate across the inflammatory cells to the indigenous cells to be transfected.
- Tris-EDTA is the buffer of choice for DNA due primarily to it's inhibitory effect on nucleases. It is known that storage of DNA in other buffers or plain water results in degradation of the DNA even at 4o C (Wolff, et al. ,
- the polymer release system can be loaded to deliver plain DNA or DNA with buffer salts to be used as carriers or protecting agents depending on the choice of buffer used.
- gene therapy for cancer therapeutics either targets the cells of the immune system to enhance their ability to kill malignant cells or directly targets the cancer cells to regulate their proliferation or enhance some cellular function which will result in a stronger activation of the immune response.
- the well known "foreign body” host response can be used to an advantage as this migration of lymphocytes and antigen presenting cells raises the possibility of directing the transfection to these specific cell populations.
- Tumors elicit both the humoral and cell- mediated immune response, and lymphocytes, particularly cytotoxic T cells and NK cells, as well as macrophages, are known to play a crucial role in tumor elimination.
- Gene therapy for cancer treatment either targets these cells or the malignant cells themselves.
- An implant releasing naked DNA for long term functional gene transfer which can target inflammatory cells and/or tumor cells could significantly improve cancer therapy.
- the approaches used include upregulation of class I MHC expression, transduction of antigen presenting cells with tumor-specific antigens, cytokine immunotherapy, transfection of tumor cells with tumor suppressor genes and anti-sense therapy.
- the malignant transformation of cells is often characterized by a reduction of class I MHC expression leading to a severe depression of the
- TNF tumor necrosis factor
- p53 tumor suppressor genes
- TNF tumor angiogenesis factor
- the immune system can be activated and induced to attack specific cells using cytokines such as Proleukin or monoclonal antibodies.
- cytokines such as Proleukin or monoclonal antibodies.
- cancer cells proliferate in part due to a decreased immune response against the transformed cells.
- the matrices described herein provide a means to allow recognition and provocation of a response to cancer cells.
- genes coding for antigens, such as the aberrant epithelial mucin of breast cancer, and monoclonal antibodies directed against tumor antigens have been shown to have potential in stimulating immune destruction of malignant cells. These genes, alone or in combination with monoclonal antibodies, can be delivered to the tumor sites in the polymeric matrices to achieve inhibition of the tumor cells.
- Cancer cells can also be treated by introducing chemotherapy drug resistant genes into healthy cells to protect them against the toxicity of drug therapy, or by the insertion of appropriate vectors containing cytotoxic genes or blocking genes into a tumor mass to eliminate cancer cells.
- the immune system is specifically stimulated against antigens or proteins on the surface of the cancer cells.
- vi tro the cells can be removed from a patient, the gene inserted into the cell and the cells reintroduced into the patient.
- the gene can be directly introduced into the body either systematically or in localized sites.
- Another approach is to use suicide genes that cause cell death when they are activated or when their product is combined with a pharmaceutical.
- the primary limitation of the method is the fact that the gene should be targeted to the cancer cell and not to normal cell.
- Current approach to overcome the problem is direct injection of the vectors into a localized area where normal cells do not proliferate. This would be greatly facilitated using the polymeric devices described herein.
- the advantages of polymeric devices in this setting include continuous and protracted release of the incorporated pharmaceutical. This increases the likelihood that the intended purposes, for example, treatment of cancerous cells, will be achieved. Examples
- Example 1 Expression of linear and supercoiled plasmid DNA encapsulated in polymeric implants in muscle tissue . of rats.
- the study described in this example confirms the feasibility of in vivo transfections using biodegradable polyester blends to release linear or supercoiled plasmid DNA. Although only short term expression was studied in this study, polymer devices releasing drugs offer the potential for sustained long term delivery of naked DNA.
- Marker genes are used to study the movement of engineered cells containing exogenous genes, as well as the vectors and genes introduced with the vectors, to insure that the genes remain where they are introduced. Almost all of the initial research into gene therapy is with marker genes. Preferred marker genes are those whose product is innocuous and which can be readily detected by simple laboratory tools. An appropriate marker gene is ⁇ - galactosidase (/3-gal) , since expression is readily detected by addition of X-gal, a substrate which yields a blue color when the active enzyme is present.
- Example 2 In vitro transfection with pRSV ⁇ - gal. NIH3T3 fibroblasts were plated onto a 6 well tissue culture dish with 1 ml of D-MEM (10% Fetal calf serum with penicillin/streptomycin) . 24 hours after plating, the cells were transfected with pRSV
- Example 3 Duration of Expression with pSV ⁇ - gal DNA Encapsulated Into PLA Blends.
- This film was incubated with 1.0 ml of TE buffer at 37°C and sample supernatants tested at 24 hours and at 4 days for the presence of released DNA. DNA was assayed by agarose gel electrophoresis on the supernatants.
- Rat ID Left Right Implant Duration Three rats received DNA/PLA in their left hamstring and control/PLA in their right hamstring. Pellets were inserted into incised hamstrings and the muscles closed with 6-0 Vicryl. Three rats received an injection of pSV /3-gal plasmids (20 ⁇ g in 100 ⁇ l of TE buffer) over a minute long period in their left leg and 100 ⁇ l of plain TE buffer in their right leg as controls. The site of injection was marked with suture. Rat ID Left Right Implant Duration
- Rats were perfused with PBS/heparin, followed by 4% paraf ormaldehyde , and post -fixed in 4% paraformaldehyde followed by 15% and 25% sucrose/PBS .
- Excised muscles were cut with a cryostat and stained with X-Gal .
- Tn vi tro release studies indicate that plasmid DNA can be incorporated into polymers without degradation through manufacturing processes and released in functional form for possible uptake by surrounding cells.
- Plasmid DNA was incorporated into a non- degradable elastomer, ethylene vinyl acetate copolymer (EVAc) and implanted into the same site in different animals as PLA/PCL implants.
- EVAc is a very biocompatible polymer which can be manufactured into a icroporous structure through which DNA can diffuse into the surrounding tissue.
- Encapsulation of pRSV 3-gal into Polymers. pRSV /3-gal in HB101 was purchased from the
- the plasmids were grown and purified with Promega's Maxi Prep. 1 ml of a 0.1% solution of ELVAX40 (Dupont) in methylene chloride was vortexed with 645.2 ⁇ l of pRSV /3-gal (200 ⁇ g) , frozen in liquid nitrogen and lyophilized. The resulting mixture was extruded at 55°C into a rod shaped form.
- PLA (2K) and PCL (112K) were dissolved in methylene chloride in a 3:1 ratio and 80 mg of the polymer vortexed with 322.6 ⁇ l of pRSV /3-gal (100 ⁇ g) .
- the mixture was left in the refrigerator for 2 days and lyophilized.
- Histological staining with X-gal reveals positive staining of muscle cells as well as inflammatory cells in close proximity to the EVAc polymeric implant at two weeks post-implantation.
- the PLA/PCL implant reveals positive staining of mostly inflammatory cells only, in accordance with the earlier data regarding biodegradable polymers.
- biodegradable or non- degradable polymer implant can be used to target delivery to inflammatory cells or tissue cells (for example, muscle) .
- tissue cells for example, muscle
- Comparison of PLA/PCL and the EVAc implants illustrates the different transfected cell populations. Specifically, the PLA/PCL implant results in almost exclusive transfection of inflammatory cells while the EVAc implant results in a large number of transfected muscle cells.
- Example 5 Stability of plasmids during manufacturing processes. Plasmid DNA is known to be sensitive to high temperatures, physical manipulations and other such factors. Because fabrication techniques require different manipulation of plasmids, methods must be selected to avoid substantial degradation of plasmids. The following studies were conducted to determine the effect of exposure of plasmids to heating, sonication and solvents such as methylene chloride, as analyzed by agarose gel electrophoresis for changes in topology and/or degradation.
- Lyophilized plasmids were added to dry polymer (PCL) and heated up to 85 C for 5 minutes and swirled into a 85oC corn oil bath as per hot melt microsphere preparation protocols. Electrophoresis of extracted plasmids indicate that the majority of the loaded plasmids had lost their supercoiled topology and degraded into a linear form.
- Example 6 In vi tro release assay. In vi tro evaluation of plasmid releasing polymer systems was performed by incubating the devices in buffers such as Tris-EDTA and periodically replacing the supernatant with fresh buffer. The incubation buffer was analyzed for plasmids with agarose gel electrophoresis to assess plasmid topology. In addition, the plasmids present in the release buffers were precipitated with the PromegaTM Profection Calcium Phosphate Mammalian Transfection System and transfected into C2C12 murine muscle cells to assay for bioactivity. Materials tested
- PLA/PCL(112k) microspheres Solvent Unavailable evaporation
- PLA/PCL(75k) microspheres Solvent removal Undegraded, detectable at one 1 week to
- PLA(2k)/PLA(300k) films Solvent cast Unavailable
- the plasmids were evaluated by agarose gel electrophoresis of the plasmids in the release buffer. The results showed degraded and intact supercoiled plasmids in the samples of pRSV/ ⁇ gal loaded PLA/PCL(112k) , pRSV/ ⁇ gal loaded PLA/PCL (112k) , and pRSV/ ⁇ gal loaded PLA/PCL (112k) .
- Agarose gel electrophoresis show undegraded plasmids in the release buffer, as reflected by clean bands, in pRSV/ ⁇ gal loaded EVAc, pRSV/ ⁇ gal loaded EVAc. and pRSV/ ⁇ gal loaded EVAc.
- the plasmids were also evaluated for biological activity. Supernatents containing the released plasmids were precipitated with calcium phosphate and transfected into C2C12 muscle cells according to PromegaTM Profection protocols. Cells were assayed for /3-galactosidase activity 48 hours post-transfection with X-gal histochemistry.
- the in vi tro transfection efficiency as measured by the number of /3-gal positive cells, of released plasmids were lower than that seen with stock plasmid DNA.
- One explanation for this difference could be due to the fact that stock plasmids are 95% monomeric supercoiled plasmids while the plasmids released from the polymers have open circular or multimeric supercoiled topology.
- the release occurs over a longer period of time than can be obtained with stock plasmid DNA.
- Example 7 Microsphere delivery in rat aorta/adventitial layer for plasmid release targeting vascular smooth muscle and endot elium.
- microspheres encapsulating plasmids could be used to target smooth muscle and endothelium for release of plasmids directly to these cells.
- a segment of the aorta/vena cava approximately 2 centimeters in length was isolated.
- a small hole in the adventitia was cut for insertion of a 27 gauge catheter.
- a blunt 25 gauge needle was used to separate the adventitia from the medial layer.
- a 27 gauge catheter was inserted into the space and the microspheres were injected.
- Example 8 Release from pSV/jSgal PLA:PCL(2:1) microspheres.
- release rate is a function of degradation rate of the polymer used for release.
- Microspheres were made by solvent removal from polylactic acid (PLA) (Mw 2k) and polycaprolactone (PCL) (Mw 75k) (2:1) . Samples contain 1% loading of pSV//3gal dispersed dry or wet.
- PLA polylactic acid
- PCL polycaprolactone
- Liposome/DNA complexes have been used for both in vi tro and in vivo transfection of mammalian cells.
- various formulations such as LIPOFECTINTM (GIBCO BRL) and TRANSFECTAMTM (Promega) have been used to enhance cellular uptake of plasmid DNA.
- liposome/DNA complexes have high transfection efficiencies when used in tissue culture, direct application of liposome/DNA for in vivo applications is somewhat limited. Limitations on the use of liposome/DNA complexes in vivo stem from their fast degradation, toxicity at high doses and inability to transfect certain cell types. In the case of skeletal muscle, direct injection of plasmid DNA is much more efficient than liposome delivery.
- liposome/DNA results in much higher expression levels compared to direct injection. This study was done to assess the feasibility of releasing liposome/DNA complexes from polymer systems. In light of the fact that lipids are soluble in organic solvents, preserving the liposome/DNA complex in intact form within the polymer matrix was the primary goal.
- the plasmid DNA and lipid solutions were vortexed briefly and allowed to form complexes for 30 min. This solution was vortexed for 10 seconds with the polymer solution, frozen in liquid nitrogen and lyophilized overnight . The resulting matrix was either used with or without heat extrusion at 50°C.
- the extruded rod and unextruded matrix (10 mg each) was incubated with C2C12 myoblasts for 48 hours. The cells were subsequently fixed and stained for /3-galactosidase activity by X-gal histochemistry.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU21214/95A AU710504B2 (en) | 1994-03-15 | 1995-03-15 | Polymeric gene delivery system |
EP95914073A EP0804249A2 (en) | 1994-03-15 | 1995-03-15 | Polymeric gene delivery system |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21366894A | 1994-03-15 | 1994-03-15 | |
US213,668 | 1994-03-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1995024929A2 true WO1995024929A2 (en) | 1995-09-21 |
WO1995024929A3 WO1995024929A3 (en) | 1995-12-28 |
Family
ID=22796022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/003307 WO1995024929A2 (en) | 1994-03-15 | 1995-03-15 | Polymeric gene delivery system |
Country Status (5)
Country | Link |
---|---|
US (4) | US6262034B1 (en) |
EP (1) | EP0804249A2 (en) |
AU (1) | AU710504B2 (en) |
CA (1) | CA2190121A1 (en) |
WO (1) | WO1995024929A2 (en) |
Cited By (151)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996005321A1 (en) * | 1994-08-17 | 1996-02-22 | Rhone-Poulenc Rorer S.A. | Gene therapy for restenosis using an adenoviral vector |
WO1997003702A1 (en) * | 1995-07-21 | 1997-02-06 | Brown University Research Foundation | A method for gene therapy using nucleic acid loaded polymeric microparticles |
WO1997017063A1 (en) * | 1995-11-09 | 1997-05-15 | Microbiological Research Authority | Microencapsulated dna for vaccination and gene therapy |
EP0844004A1 (en) * | 1995-07-03 | 1998-05-27 | Koken Company Limited | Gene preparations |
US5783567A (en) * | 1997-01-22 | 1998-07-21 | Pangaea Pharmaceuticals, Inc. | Microparticles for delivery of nucleic acid |
WO1998051279A2 (en) * | 1996-11-12 | 1998-11-19 | Microbiological Research Authority | Method of making microencapsulated dna for vaccination and gene therapy |
WO1999029304A1 (en) * | 1997-12-12 | 1999-06-17 | Massachusetts Institute Of Technology | Method for high supercoiled dna content microspheres |
US6004943A (en) * | 1995-11-27 | 1999-12-21 | Inst. Of Biomedical Engineering, Chinese Acdmy Of Med. Science | Protein-coated medical substrates for local delivery of genes and method of forming coatings on the substrates |
WO1999065463A1 (en) * | 1998-06-16 | 1999-12-23 | Ben-Gurion University Of The Negev | Active ingredient delivery systems and devices based on porous matrices |
WO1999066959A2 (en) * | 1998-06-01 | 1999-12-29 | Selective Genetics, Inc. | Compositions and methods for delivery of genetic material for altering neuronal growth, regeneration, and survival |
US6013258A (en) * | 1997-10-09 | 2000-01-11 | Zycos Inc. | Immunogenic peptides from the HPV E7 protein |
WO2000003738A1 (en) * | 1998-07-17 | 2000-01-27 | Mirus Corporation | Chelating systems for use in the delivery of compounds to cells |
US6027721A (en) * | 1996-05-20 | 2000-02-22 | Cytotherapeutics, Inc. | Device and method for encapsulated gene therapy |
EP1005374A1 (en) * | 1997-01-22 | 2000-06-07 | Zycos Inc. | Microparticles for delivery of nucleic acid |
US6143211A (en) * | 1995-07-21 | 2000-11-07 | Brown University Foundation | Process for preparing microparticles through phase inversion phenomena |
US6143037A (en) * | 1996-06-12 | 2000-11-07 | The Regents Of The University Of Michigan | Compositions and methods for coating medical devices |
US6183746B1 (en) | 1997-10-09 | 2001-02-06 | Zycos Inc. | Immunogenic peptides from the HPV E7 protein |
US6248720B1 (en) | 1996-07-03 | 2001-06-19 | Brown University Research Foundation | Method for gene therapy using nucleic acid loaded polymeric microparticles |
US6267957B1 (en) | 1998-01-20 | 2001-07-31 | Howard Green | Attaching agents to tissue with transglutaminase and a transglutaminase substrate |
US6270795B1 (en) | 1995-11-09 | 2001-08-07 | Microbiological Research Authority | Method of making microencapsulated DNA for vaccination and gene therapy |
WO2001074413A1 (en) * | 2000-04-04 | 2001-10-11 | Boston Scientific Limited | Medical devices suitable for gene therapy regimens |
US6309569B1 (en) | 1998-05-13 | 2001-10-30 | Microbiological Research Authority | Encapsulation of bioactive agents |
KR20020028419A (en) * | 2000-10-10 | 2002-04-17 | 서만석 | A method of transmitting plasmid, DNA or DNA vaccination |
US6379379B1 (en) | 1998-05-05 | 2002-04-30 | Scimed Life Systems, Inc. | Stent with smooth ends |
US6395253B2 (en) | 1998-04-23 | 2002-05-28 | The Regents Of The University Of Michigan | Microspheres containing condensed polyanionic bioactive agents and methods for their production |
EP1208212A1 (en) * | 1999-06-16 | 2002-05-29 | Bristol-Myers Squibb Company | Fibrin sealant as a transfection/transformation vehicle for gene therapy |
WO2002042325A2 (en) | 2000-10-31 | 2002-05-30 | Zycos Inc. | Cyp1b1 nucleic acids and methods of use |
US6406719B1 (en) | 1998-05-13 | 2002-06-18 | Microbiological Research Authority | Encapsulation of bioactive agents |
WO2002058752A2 (en) * | 2000-12-04 | 2002-08-01 | Medtronic, Inc. | Medical device and methods of use |
US6511957B1 (en) | 1993-02-19 | 2003-01-28 | Howard Green | Compositions containing corneocyte proteins |
US6514947B2 (en) | 1995-01-13 | 2003-02-04 | Valentis, Inc. | Formulated nucleic acid compositions and methods of administering the same for gene therapy |
US6518308B2 (en) | 2000-11-21 | 2003-02-11 | Michael P. Diamond | Compositions for adhesion prevention |
US6548302B1 (en) | 1998-06-18 | 2003-04-15 | Johns Hopkins University School Of Medicine | Polymers for delivery of nucleic acids |
WO2003044187A2 (en) * | 2001-11-16 | 2003-05-30 | Medical Research Council | Emulsion compositions |
WO2003055411A2 (en) * | 2001-12-28 | 2003-07-10 | NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen | Implantable device and the use thereof |
WO2004037175A2 (en) | 2002-10-21 | 2004-05-06 | Mgi Pharma Biologics, Inc. | Compositions and methods for treating human papillomavirus-mediated disease |
US6753015B2 (en) | 2000-09-28 | 2004-06-22 | Chiron Corporation | Microparticle compositions and methods for the manufacture thereof |
US6770740B1 (en) | 1999-07-13 | 2004-08-03 | The Regents Of The University Of Michigan | Crosslinked DNA condensate compositions and gene delivery methods |
US6884435B1 (en) * | 1997-01-30 | 2005-04-26 | Chiron Corporation | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
US6916490B1 (en) | 1998-07-23 | 2005-07-12 | UAB Research Center | Controlled release of bioactive substances |
US6998268B2 (en) | 1995-07-03 | 2006-02-14 | Dainippon Sumitomo Pharma Co. Ltd. | Gene preparations |
WO2006023603A2 (en) | 2004-08-17 | 2006-03-02 | The Johns Hopkins University | Pde5 inhibitor compositions and methods for treating cardiac indications |
US7112442B2 (en) | 1996-11-04 | 2006-09-26 | The Regents Of The University Of Michigan | Peptides for gene delivery |
WO2006105448A2 (en) | 2005-03-30 | 2006-10-05 | Minerva Biotechnologies Corporation | Proliferation of muc1 expressing cells |
US7138233B2 (en) | 1997-07-07 | 2006-11-21 | Medical Research Council | IN vitro sorting method |
US7173116B2 (en) | 2000-03-03 | 2007-02-06 | Genetronics Biomedical Corporation | Nucleic acid formulations for gene delivery and methods of use |
WO2007027559A2 (en) | 2005-08-29 | 2007-03-08 | Shashoua Victor E | Neuroprotective and neurorestorative methods and compositions |
WO2007062107A2 (en) | 2005-11-25 | 2007-05-31 | Coley Pharmaceutical Gmbh | Immunostimulatory oligoribonucleotides |
EP2058329A1 (en) | 2003-06-10 | 2009-05-13 | NsGene A/S | Improved secretion of neublastin |
EP2075254A1 (en) | 2004-03-30 | 2009-07-01 | NsGene A/S | Therapeutic use of a growth factor, NsG33 |
EP2100620A1 (en) | 1999-09-16 | 2009-09-16 | Eisai Corporation of North America | Nucleic acids encoding polyepitope polypeptides |
US7597908B2 (en) | 1997-01-30 | 2009-10-06 | Novartis Vaccines And Diagnostics, Inc. | Use of microparticles with adsorbed antigen to stimulate immune responses |
US7674777B2 (en) | 1994-07-15 | 2010-03-09 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US7700715B2 (en) | 2000-11-27 | 2010-04-20 | Minerva Biotechnologies Corporation | Diagnostic tumor markers, drug screening for tumorigenesis inhibition, and compositions and methods for treatment of cancer |
EP2210617A1 (en) | 2003-10-20 | 2010-07-28 | NsGene A/S | Mammalian cells secreting Neurturin and their therapeutic use |
WO2010083842A2 (en) | 2009-01-23 | 2010-07-29 | Nsgene A/S | Expression of neuropeptides in mammalian cells |
US20100272771A1 (en) * | 2009-04-23 | 2010-10-28 | Ed Harlow | Device including bone cage and method for treatment of disease in a subject |
US7838502B2 (en) | 2005-05-06 | 2010-11-23 | University Of Massachusetts Medical School | Compositions and methods to modulate H. influenzae pathogenesis |
US7842457B2 (en) | 2003-01-29 | 2010-11-30 | 454 Life Sciences Corporation | Bead emulsion nucleic acid amplification |
EP2267029A2 (en) | 1999-09-03 | 2010-12-29 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of inflammatory disease using Cadherin-11 modulating agents |
EP2325301A1 (en) | 2003-02-11 | 2011-05-25 | Shire Human Genetic Therapies, Inc. | Diagnosis and treatment of multiple sulfatase deficiency and others using a formylglycine generating enzyme (FGE) |
EP2336359A1 (en) | 2002-05-09 | 2011-06-22 | The Brigham and Women's Hospital, Inc. | 1L1RL-1 as a cardiovascular disease marker and therapeutic target |
WO2011089595A2 (en) | 2010-01-19 | 2011-07-28 | Polypid Ltd. | Sustained-release nucleic acid matrix compositions |
EP2363410A1 (en) | 2002-11-27 | 2011-09-07 | Minerva Biotechnologies Corporation | Isoforms of MUC1 |
EP2374451A2 (en) | 2005-07-27 | 2011-10-12 | University of Florida Research Foundation, Inc. | Histone deacetylase inhibitors (HDAC) that correct protein misfolding and uses thereof |
EP2377528A2 (en) | 2003-06-12 | 2011-10-19 | The Board of Regents of the University of Colorado | Fatty acid metabolism inhibitors for use in the treatment of cancer |
US8048627B2 (en) | 2003-07-05 | 2011-11-01 | The Johns Hopkins University | Method and compositions for detection and enumeration of genetic variations |
EP2385370A1 (en) | 2008-04-10 | 2011-11-09 | Massachusetts Institute of Technology (MIT) | Methods for identification and use of agents targeting cancer stem cells |
US8119153B2 (en) | 2004-08-26 | 2012-02-21 | Boston Scientific Scimed, Inc. | Stents with drug eluting coatings |
US8148340B2 (en) | 1994-07-15 | 2012-04-03 | The United States Of America As Represented By The Department Of Health And Human Services | Immunomodulatory oligonucleotides |
WO2012041328A1 (en) | 2010-10-01 | 2012-04-05 | Nsgene A/S | Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain |
EP2439213A1 (en) | 2004-04-21 | 2012-04-11 | The Brigham and Women's Hospital, Inc. | Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof |
WO2012174064A1 (en) | 2011-06-14 | 2012-12-20 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
US8354258B2 (en) | 2005-12-14 | 2013-01-15 | The Invention Science Fund I, Llc | Diatom device |
WO2013013061A1 (en) | 2011-07-19 | 2013-01-24 | University Of Vermont And State Agricultural College | Methods and compounds for treating cancer |
WO2013082275A1 (en) | 2011-11-30 | 2013-06-06 | Trustees Of Boston College | Inhibitors of phosphodiesterases 11 (pde11) and methods of use to elevate cortisol production |
US8481068B2 (en) | 2005-12-14 | 2013-07-09 | The Invention Science Fund I, Llc | Bone cell delivery device |
US8492143B2 (en) | 2005-12-14 | 2013-07-23 | The Invention Science Fund I, Llc | Bone delivery device |
US8524444B2 (en) | 2007-06-15 | 2013-09-03 | President And Fellows Of Harvard College | Methods and compositions for detections and modulating O-glycosylation |
US8524829B2 (en) | 2001-08-08 | 2013-09-03 | Brown University Research Foundation | Methods for micronization of hydrophobic drugs |
EP2633864A1 (en) | 2008-07-25 | 2013-09-04 | The Regents of the University of Colorado | Clip inhibitors and methods of modulating immune function |
EP2644205A1 (en) | 2007-04-12 | 2013-10-02 | The Brigham and Women's Hospital, Inc. | Targeting ABCB5 for cancer therapy |
US8574599B1 (en) | 1998-05-22 | 2013-11-05 | Ottawa Hospital Research Institute | Methods and products for inducing mucosal immunity |
US8598342B2 (en) | 2008-06-12 | 2013-12-03 | President And Fellows Of Harvard College | Methods and compounds for antimicrobial intervention |
US8691545B2 (en) | 2005-12-14 | 2014-04-08 | The Invention Science Fund I, Llc | Bone semi-permeable device |
US8877242B2 (en) | 2008-07-14 | 2014-11-04 | Polypid Ltd. | Sustained-release drug carrier composition |
US8900865B2 (en) | 2005-12-14 | 2014-12-02 | The Invention Science Fund I, Llc | Blood brain barrier device |
US8957075B2 (en) | 2009-06-01 | 2015-02-17 | President And Fellows Of Harvard College | O-GlcNAc transferase inhibitors and uses thereof |
US8992979B2 (en) | 2009-07-14 | 2015-03-31 | Polypid Ltd. | Sustained-release drug carrier composition |
US9005944B2 (en) | 2005-12-14 | 2015-04-14 | The Invention Science Fund I, Llc | Bone cell delivery device |
US9017623B2 (en) | 2007-02-06 | 2015-04-28 | Raindance Technologies, Inc. | Manipulation of fluids and reactions in microfluidic systems |
US9029083B2 (en) | 2004-10-08 | 2015-05-12 | Medical Research Council | Vitro evolution in microfluidic systems |
US9028859B2 (en) | 2006-07-07 | 2015-05-12 | Advanced Cardiovascular Systems, Inc. | Phase-separated block copolymer coatings for implantable medical devices |
US9056155B1 (en) | 2007-05-29 | 2015-06-16 | Abbott Cardiovascular Systems Inc. | Coatings having an elastic primer layer |
US9068699B2 (en) | 2007-04-19 | 2015-06-30 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
US9067000B2 (en) | 2004-10-27 | 2015-06-30 | Abbott Cardiovascular Systems Inc. | End-capped poly(ester amide) copolymers |
US9074242B2 (en) | 2010-02-12 | 2015-07-07 | Raindance Technologies, Inc. | Digital analyte analysis |
US9084671B2 (en) | 2002-06-21 | 2015-07-21 | Advanced Cardiovascular Systems, Inc. | Methods of forming a micronized peptide coated stent |
EP2910637A1 (en) | 2008-05-20 | 2015-08-26 | University of Florida Research Foundation, Inc. | Vectors for delivery of light-sensitive proteins and methods of use |
US9119858B2 (en) | 2012-08-21 | 2015-09-01 | Genesys Research Institute, Inc. | Compositions and methods for treating or preventing anthracycline induced cardiotoxicity |
US9175162B2 (en) | 2003-05-08 | 2015-11-03 | Advanced Cardiovascular Systems, Inc. | Methods for forming stent coatings comprising hydrophilic additives |
EP2944628A1 (en) | 2011-11-30 | 2015-11-18 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
US9200287B2 (en) | 2007-05-18 | 2015-12-01 | Adiutide Pharmaceuticals Gmbh | Phosphate-modified oligonucleotide analogs with enhanced immunostimulatory activity |
EP3006043A1 (en) | 2002-04-04 | 2016-04-13 | Zoetis Belgium S.A. | Immunostimulatory g,u-containing oligoribonucleotides |
US9375445B2 (en) | 2004-06-18 | 2016-06-28 | Abbott Cardiovascular Systems Inc. | Heparin prodrugs and drug delivery stents formed therefrom |
US20160184234A1 (en) * | 2013-11-07 | 2016-06-30 | The General Hospital Corporation | Eluting Matrix and Uses Thereof |
WO2016134110A1 (en) | 2015-02-18 | 2016-08-25 | University Of Vermont And State Agricultural College | Mcj agonists and uses therefor |
EP3100723A1 (en) | 2009-06-16 | 2016-12-07 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
WO2017011356A2 (en) | 2015-07-10 | 2017-01-19 | University Of Vermont And State Agricultural College | Methods and compositions to treat drug-induced diseases and conditions |
EP3130923A1 (en) | 2008-11-14 | 2017-02-15 | The Brigham and Women's Hospital, Inc. | Therapeutic and diagnostic methods relating to cancer stem cells |
WO2017029556A1 (en) | 2015-08-20 | 2017-02-23 | Asociación Centro De Investigación Cooperativa En Biociencias - Cis Biogune | Methods and compositions to treat liver diseases and conditions |
US9580558B2 (en) | 2004-07-30 | 2017-02-28 | Abbott Cardiovascular Systems Inc. | Polymers containing siloxane monomers |
EP3138915A1 (en) | 2010-05-04 | 2017-03-08 | The Brigham and Women's Hospital, Inc. | Detection and treatment of fibrosis |
US9758606B2 (en) | 2012-07-31 | 2017-09-12 | The Trustees Of Columbia University In The City Of New York | Cyclopropenium polymers and methods for making the same |
WO2017198839A1 (en) | 2016-05-20 | 2017-11-23 | Vihinen Mauno | Destabilising domains for conditionally stabilising a protein |
US9839890B2 (en) | 2004-03-31 | 2017-12-12 | National Science Foundation | Compartmentalised combinatorial chemistry by microfluidic control |
WO2017213695A1 (en) | 2016-06-07 | 2017-12-14 | The Brigham And Women's Hospital, Inc. | Compositions and methods relating to t peripheral helper cells in autoantibody-associated conditions |
US9857303B2 (en) | 2003-03-31 | 2018-01-02 | Medical Research Council | Selection by compartmentalised screening |
WO2018145109A1 (en) | 2017-02-06 | 2018-08-09 | Massachusetts Institute Of Technology | Methods and products related to glutaminase inhibitors |
US10052605B2 (en) | 2003-03-31 | 2018-08-21 | Medical Research Council | Method of synthesis and testing of combinatorial libraries using microcapsules |
US10064982B2 (en) | 2001-06-27 | 2018-09-04 | Abbott Cardiovascular Systems Inc. | PDLLA stent coating |
US10076591B2 (en) | 2010-03-31 | 2018-09-18 | Abbott Cardiovascular Systems Inc. | Absorbable coating for implantable device |
US10106778B2 (en) | 2012-11-08 | 2018-10-23 | Whitehead Institute For Biomedical Research | Selective targeting of cancer stem cells |
US10130687B2 (en) | 2011-01-05 | 2018-11-20 | Rhode Island Hospital | Compositions and methods for the treatment of orthopedic disease or injury |
US10351905B2 (en) | 2010-02-12 | 2019-07-16 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
US10398672B2 (en) | 2014-04-29 | 2019-09-03 | Whitehead Institute For Biomedical Research | Methods and compositions for targeting cancer stem cells |
US10520500B2 (en) | 2009-10-09 | 2019-12-31 | Abdeslam El Harrak | Labelled silica-based nanomaterial with enhanced properties and uses thereof |
US10533998B2 (en) | 2008-07-18 | 2020-01-14 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
US10647981B1 (en) | 2015-09-08 | 2020-05-12 | Bio-Rad Laboratories, Inc. | Nucleic acid library generation methods and compositions |
US10703821B2 (en) | 2005-03-30 | 2020-07-07 | Minerva Biotechnologies Corporation | Method for stimulating or enhancing proliferation of cells by activating the mucin 1 (MUC1) receptor |
US10837883B2 (en) | 2009-12-23 | 2020-11-17 | Bio-Rad Laboratories, Inc. | Microfluidic systems and methods for reducing the exchange of molecules between droplets |
US11077415B2 (en) | 2011-02-11 | 2021-08-03 | Bio-Rad Laboratories, Inc. | Methods for forming mixed droplets |
WO2021168373A1 (en) | 2020-02-21 | 2021-08-26 | Mitotherapeutix Llc | Compositions and methods for inhibiting expression of methylation-controlled j-protein (mcj) |
WO2021222222A1 (en) | 2020-04-27 | 2021-11-04 | Mccray Jr Paul B | Compositions and methods for the treatment of cystic fibrosis |
US11168353B2 (en) | 2011-02-18 | 2021-11-09 | Bio-Rad Laboratories, Inc. | Compositions and methods for molecular labeling |
US11174509B2 (en) | 2013-12-12 | 2021-11-16 | Bio-Rad Laboratories, Inc. | Distinguishing rare variations in a nucleic acid sequence from a sample |
US11193176B2 (en) | 2013-12-31 | 2021-12-07 | Bio-Rad Laboratories, Inc. | Method for detecting and quantifying latent retroviral RNA species |
EP3936144A1 (en) | 2012-07-11 | 2022-01-12 | The University of Vermont and State Agriculture College | Methods and compositions for metabolic regulation |
US11225512B2 (en) | 2017-04-27 | 2022-01-18 | University Of New Hampshire | Compositions and methods for ceramide-elevating therapeutic strategies |
US11242374B2 (en) | 2015-01-22 | 2022-02-08 | Brown University | Minimally-invasive and activity-dependent control of excitable cells |
US11268887B2 (en) | 2009-03-23 | 2022-03-08 | Bio-Rad Laboratories, Inc. | Manipulation of microfluidic droplets |
US11351510B2 (en) | 2006-05-11 | 2022-06-07 | Bio-Rad Laboratories, Inc. | Microfluidic devices |
US11390917B2 (en) | 2010-02-12 | 2022-07-19 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
WO2022233989A1 (en) | 2021-05-06 | 2022-11-10 | Hoba Therapeutics Aps | Prevention and treatment of chemotherapy-induced neuropathic pain |
US11511242B2 (en) | 2008-07-18 | 2022-11-29 | Bio-Rad Laboratories, Inc. | Droplet libraries |
US11635427B2 (en) | 2010-09-30 | 2023-04-25 | Bio-Rad Laboratories, Inc. | Sandwich assays in droplets |
WO2023104960A1 (en) | 2021-12-10 | 2023-06-15 | Hoba Therapeutics Aps | Treatment of nociceptive pain |
US11746159B2 (en) | 2015-02-10 | 2023-09-05 | Minerva Biotechnologies Corporation | Humanized anti-MUC1* antibodies |
US11898160B2 (en) | 2008-10-09 | 2024-02-13 | Minerva Biotechnologies Corporation | Method for maintaining pluripotency in cells |
US11898193B2 (en) | 2011-07-20 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Manipulating droplet size |
US11901041B2 (en) | 2013-10-04 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Digital analysis of nucleic acid modification |
Families Citing this family (198)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6117643A (en) * | 1997-11-25 | 2000-09-12 | Ut Battelle, Llc | Bioluminescent bioreporter integrated circuit |
FR2772047B1 (en) * | 1997-12-05 | 2004-04-09 | Ct Nat D Etudes Veterinaires E | GENOMIC SEQUENCE AND POLYPEPTIDES OF CIRCOVIRUS ASSOCIATED WITH PIGLET LOSS DISEASE (MAP), APPLICATIONS TO DIAGNOSIS AND TO PREVENTION AND / OR TREATMENT OF INFECTION |
FR2779962B1 (en) * | 1998-06-17 | 2002-12-06 | Karim Ioualalen | COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION IN THE FORM OF PEARLS AND METHODS FOR THE PREPARATION |
GB9900298D0 (en) * | 1999-01-07 | 1999-02-24 | Medical Res Council | Optical sorting method |
US6943152B1 (en) * | 1999-06-10 | 2005-09-13 | Merial | DNA vaccine-PCV |
EP1074248A1 (en) * | 1999-07-08 | 2001-02-07 | Arnold Hilgers | Delivery system for biological material |
US7030097B1 (en) * | 1999-07-14 | 2006-04-18 | Cornell Research Foundation, Inc. | Controlled nucleic acid delivery systems |
US7807211B2 (en) | 1999-09-03 | 2010-10-05 | Advanced Cardiovascular Systems, Inc. | Thermal treatment of an implantable medical device |
US20070032853A1 (en) | 2002-03-27 | 2007-02-08 | Hossainy Syed F | 40-O-(2-hydroxy)ethyl-rapamycin coated stent |
US20050037086A1 (en) * | 1999-11-19 | 2005-02-17 | Zycos Inc., A Delaware Corporation | Continuous-flow method for preparing microparticles |
ES2170622B1 (en) * | 1999-12-03 | 2004-05-16 | Consejo Superior De Investigaciones Cientificas | CLONES AND INFECTIVE VECTORS DERIVED FROM CORONAVIRUS AND ITS APPLICATIONS. |
US20010007083A1 (en) * | 1999-12-29 | 2001-07-05 | Roorda Wouter E. | Device and active component for inhibiting formation of thrombus-inflammatory cell matrix |
BR0108959A (en) * | 2000-03-03 | 2003-10-14 | Valentis Inc | Improved poloxamer or poloxamine compositions for nucleic acid delivery |
US8460367B2 (en) | 2000-03-15 | 2013-06-11 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
US8088060B2 (en) | 2000-03-15 | 2012-01-03 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
US9522217B2 (en) | 2000-03-15 | 2016-12-20 | Orbusneich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods for using same |
US6953560B1 (en) | 2000-09-28 | 2005-10-11 | Advanced Cardiovascular Systems, Inc. | Barriers for polymer-coated implantable medical devices and methods for making the same |
US7807210B1 (en) | 2000-10-31 | 2010-10-05 | Advanced Cardiovascular Systems, Inc. | Hemocompatible polymers on hydrophobic porous polymers |
GB0100761D0 (en) | 2001-01-11 | 2001-02-21 | Biocompatibles Ltd | Drug delivery from stents |
US6780424B2 (en) * | 2001-03-30 | 2004-08-24 | Charles David Claude | Controlled morphologies in polymer drug for release of drugs from polymer films |
US6764505B1 (en) * | 2001-04-12 | 2004-07-20 | Advanced Cardiovascular Systems, Inc. | Variable surface area stent |
US7862495B2 (en) * | 2001-05-31 | 2011-01-04 | Advanced Cardiovascular Systems, Inc. | Radiation or drug delivery source with activity gradient to minimize edge effects |
US7247313B2 (en) * | 2001-06-27 | 2007-07-24 | Advanced Cardiovascular Systems, Inc. | Polyacrylates coatings for implantable medical devices |
US6695920B1 (en) | 2001-06-27 | 2004-02-24 | Advanced Cardiovascular Systems, Inc. | Mandrel for supporting a stent and a method of using the mandrel to coat a stent |
US7175873B1 (en) | 2001-06-27 | 2007-02-13 | Advanced Cardiovascular Systems, Inc. | Rate limiting barriers for implantable devices and methods for fabrication thereof |
US6656216B1 (en) | 2001-06-29 | 2003-12-02 | Advanced Cardiovascular Systems, Inc. | Composite stent with regioselective material |
US7682669B1 (en) * | 2001-07-30 | 2010-03-23 | Advanced Cardiovascular Systems, Inc. | Methods for covalently immobilizing anti-thrombogenic material into a coating on a medical device |
US8303651B1 (en) | 2001-09-07 | 2012-11-06 | Advanced Cardiovascular Systems, Inc. | Polymeric coating for reducing the rate of release of a therapeutic substance from a stent |
US20030073961A1 (en) * | 2001-09-28 | 2003-04-17 | Happ Dorrie M. | Medical device containing light-protected therapeutic agent and a method for fabricating thereof |
CN1646501A (en) * | 2002-02-07 | 2005-07-27 | 科瓦伦特合伙责任有限公司 | Nanofilm and membrane compositions |
US20040034223A1 (en) * | 2002-02-07 | 2004-02-19 | Covalent Partners, Llc. | Amphiphilic molecular modules and constructs based thereon |
AU2003219805B2 (en) * | 2002-02-15 | 2009-06-04 | Eisai Inc. | Electroporation methods for introducing bioactive agents into cells |
US7635463B2 (en) | 2002-02-27 | 2009-12-22 | Pharmain Corporation | Compositions for delivery of therapeutics and other materials |
JP2005524657A (en) * | 2002-02-27 | 2005-08-18 | ファーメイン, エルティーディー. | Compositions for delivering therapeutic agents and other substances, and methods of making and using said compositions |
US20050260259A1 (en) * | 2004-04-23 | 2005-11-24 | Bolotin Elijah M | Compositions for treatment with glucagon-like peptide, and methods of making and using the same |
US7459164B2 (en) | 2002-05-28 | 2008-12-02 | Botulinum Toxin Research Associates, Inc. | Composition for therapeutic and cosmetic botulinum toxin |
US7691394B2 (en) * | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
US7056523B1 (en) | 2002-06-21 | 2006-06-06 | Advanced Cardiovascular Systems, Inc. | Implantable medical devices incorporating chemically conjugated polymers and oligomers of L-arginine |
US7033602B1 (en) | 2002-06-21 | 2006-04-25 | Advanced Cardiovascular Systems, Inc. | Polycationic peptide coatings and methods of coating implantable medical devices |
US7217426B1 (en) | 2002-06-21 | 2007-05-15 | Advanced Cardiovascular Systems, Inc. | Coatings containing polycationic peptides for cardiovascular therapy |
US7794743B2 (en) | 2002-06-21 | 2010-09-14 | Advanced Cardiovascular Systems, Inc. | Polycationic peptide coatings and methods of making the same |
US7622146B2 (en) * | 2002-07-18 | 2009-11-24 | Advanced Cardiovascular Systems, Inc. | Rate limiting barriers for implantable devices and methods for fabrication thereof |
US20040106741A1 (en) * | 2002-09-17 | 2004-06-03 | Kriesel Joshua W. | Nanofilm compositions with polymeric components |
US7718189B2 (en) | 2002-10-29 | 2010-05-18 | Transave, Inc. | Sustained release of antiinfectives |
US20040220081A1 (en) * | 2002-10-30 | 2004-11-04 | Spherics, Inc. | Nanoparticulate bioactive agents |
EP1575638A1 (en) * | 2002-11-08 | 2005-09-21 | Conor Medsystems, Inc. | Expandable medical device and method for treating chronic total occlusions with local delivery of an angiogenic factor |
US7169178B1 (en) | 2002-11-12 | 2007-01-30 | Advanced Cardiovascular Systems, Inc. | Stent with drug coating |
US7776926B1 (en) | 2002-12-11 | 2010-08-17 | Advanced Cardiovascular Systems, Inc. | Biocompatible coating for implantable medical devices |
US7758880B2 (en) | 2002-12-11 | 2010-07-20 | Advanced Cardiovascular Systems, Inc. | Biocompatible polyacrylate compositions for medical applications |
US7074276B1 (en) | 2002-12-12 | 2006-07-11 | Advanced Cardiovascular Systems, Inc. | Clamp mandrel fixture and a method of using the same to minimize coating defects |
US7758881B2 (en) | 2004-06-30 | 2010-07-20 | Advanced Cardiovascular Systems, Inc. | Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device |
US20060002968A1 (en) | 2004-06-30 | 2006-01-05 | Gordon Stewart | Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders |
US8435550B2 (en) | 2002-12-16 | 2013-05-07 | Abbot Cardiovascular Systems Inc. | Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device |
KR20050094817A (en) * | 2002-12-20 | 2005-09-28 | 보툴리늄 톡신 리서치 어쏘시에이츠, 인크. | Improved pharmaceutical botulinum toxin compositions |
US8791171B2 (en) | 2003-05-01 | 2014-07-29 | Abbott Cardiovascular Systems Inc. | Biodegradable coatings for implantable medical devices |
US20050118344A1 (en) | 2003-12-01 | 2005-06-02 | Pacetti Stephen D. | Temperature controlled crimping |
US7785512B1 (en) | 2003-07-31 | 2010-08-31 | Advanced Cardiovascular Systems, Inc. | Method and system of controlled temperature mixing and molding of polymers with active agents for implantable medical devices |
US7198675B2 (en) | 2003-09-30 | 2007-04-03 | Advanced Cardiovascular Systems | Stent mandrel fixture and method for selectively coating surfaces of a stent |
US7261946B2 (en) | 2003-11-14 | 2007-08-28 | Advanced Cardiovascular Systems, Inc. | Block copolymers of acrylates and methacrylates with fluoroalkenes |
US9114198B2 (en) | 2003-11-19 | 2015-08-25 | Advanced Cardiovascular Systems, Inc. | Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same |
US8192752B2 (en) | 2003-11-21 | 2012-06-05 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable devices including biologically erodable polyesters and methods for fabricating the same |
US7435788B2 (en) | 2003-12-19 | 2008-10-14 | Advanced Cardiovascular Systems, Inc. | Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents |
ES2432040T3 (en) * | 2004-01-28 | 2013-11-29 | 454 Life Sciences Corporation | Nucleic acid amplification with continuous flow emulsion |
US8685431B2 (en) | 2004-03-16 | 2014-04-01 | Advanced Cardiovascular Systems, Inc. | Biologically absorbable coatings for implantable devices based on copolymers having ester bonds and methods for fabricating the same |
US20050221339A1 (en) | 2004-03-31 | 2005-10-06 | Medical Research Council Harvard University | Compartmentalised screening by microfluidic control |
US8778014B1 (en) | 2004-03-31 | 2014-07-15 | Advanced Cardiovascular Systems, Inc. | Coatings for preventing balloon damage to polymer coated stents |
US7820732B2 (en) | 2004-04-30 | 2010-10-26 | Advanced Cardiovascular Systems, Inc. | Methods for modulating thermal and mechanical properties of coatings on implantable devices |
US8293890B2 (en) | 2004-04-30 | 2012-10-23 | Advanced Cardiovascular Systems, Inc. | Hyaluronic acid based copolymers |
CA2567741A1 (en) * | 2004-05-25 | 2006-03-30 | Chimeracore, Inc. | Self-assembling nanoparticle drug delivery system |
WO2005118016A1 (en) * | 2004-05-27 | 2005-12-15 | Medtronic, Inc. | Medical device comprising a biologically active agent |
US9561309B2 (en) | 2004-05-27 | 2017-02-07 | Advanced Cardiovascular Systems, Inc. | Antifouling heparin coatings |
US7217428B2 (en) * | 2004-05-28 | 2007-05-15 | Technology Innovations Llc | Drug delivery apparatus utilizing cantilever |
US20050267556A1 (en) * | 2004-05-28 | 2005-12-01 | Allan Shuros | Drug eluting implants to prevent cardiac apoptosis |
US20050271700A1 (en) * | 2004-06-03 | 2005-12-08 | Desnoyer Jessica R | Poly(ester amide) coating composition for implantable devices |
US20050287184A1 (en) | 2004-06-29 | 2005-12-29 | Hossainy Syed F A | Drug-delivery stent formulations for restenosis and vulnerable plaque |
US8357391B2 (en) | 2004-07-30 | 2013-01-22 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable devices comprising poly (hydroxy-alkanoates) and diacid linkages |
EP2594259A1 (en) | 2004-08-04 | 2013-05-22 | Brookwood Pharmaceuticals, Inc. | Methods for manufacturing delivery devices and devices thereof |
US7648727B2 (en) | 2004-08-26 | 2010-01-19 | Advanced Cardiovascular Systems, Inc. | Methods for manufacturing a coated stent-balloon assembly |
US7244443B2 (en) | 2004-08-31 | 2007-07-17 | Advanced Cardiovascular Systems, Inc. | Polymers of fluorinated monomers and hydrophilic monomers |
US7229471B2 (en) * | 2004-09-10 | 2007-06-12 | Advanced Cardiovascular Systems, Inc. | Compositions containing fast-leaching plasticizers for improved performance of medical devices |
US8110211B2 (en) | 2004-09-22 | 2012-02-07 | Advanced Cardiovascular Systems, Inc. | Medicated coatings for implantable medical devices including polyacrylates |
US20060078624A1 (en) * | 2004-09-29 | 2006-04-13 | Samuel Zalipsky | Microparticles and nanoparticles containing a lipopolymer |
US9011831B2 (en) | 2004-09-30 | 2015-04-21 | Advanced Cardiovascular Systems, Inc. | Methacrylate copolymers for medical devices |
US7390497B2 (en) | 2004-10-29 | 2008-06-24 | Advanced Cardiovascular Systems, Inc. | Poly(ester amide) filler blends for modulation of coating properties |
US8663225B2 (en) | 2004-11-12 | 2014-03-04 | Medtronic, Inc. | Hydrogel bone void filler |
US8609123B2 (en) | 2004-11-29 | 2013-12-17 | Advanced Cardiovascular Systems, Inc. | Derivatized poly(ester amide) as a biobeneficial coating |
US7892592B1 (en) | 2004-11-30 | 2011-02-22 | Advanced Cardiovascular Systems, Inc. | Coating abluminal surfaces of stents and other implantable medical devices |
US7604818B2 (en) | 2004-12-22 | 2009-10-20 | Advanced Cardiovascular Systems, Inc. | Polymers of fluorinated monomers and hydrocarbon monomers |
US7419504B2 (en) | 2004-12-27 | 2008-09-02 | Advanced Cardiovascular Systems, Inc. | Poly(ester amide) block copolymers |
US8007775B2 (en) | 2004-12-30 | 2011-08-30 | Advanced Cardiovascular Systems, Inc. | Polymers containing poly(hydroxyalkanoates) and agents for use with medical articles and methods of fabricating the same |
EP1979012A2 (en) * | 2005-02-15 | 2008-10-15 | Stichting Voor De Technische Wetenschappen | Dna-based coatings for implants |
US7700659B2 (en) * | 2005-03-24 | 2010-04-20 | Advanced Cardiovascular Systems, Inc. | Implantable devices formed of non-fouling methacrylate or acrylate polymers |
US9381279B2 (en) | 2005-03-24 | 2016-07-05 | Abbott Cardiovascular Systems Inc. | Implantable devices formed on non-fouling methacrylate or acrylate polymers |
US20060253068A1 (en) * | 2005-04-20 | 2006-11-09 | Van Bilsen Paul | Use of biocompatible in-situ matrices for delivery of therapeutic cells to the heart |
US7795467B1 (en) | 2005-04-26 | 2010-09-14 | Advanced Cardiovascular Systems, Inc. | Bioabsorbable, biobeneficial polyurethanes for use in medical devices |
US8778375B2 (en) | 2005-04-29 | 2014-07-15 | Advanced Cardiovascular Systems, Inc. | Amorphous poly(D,L-lactide) coating |
US20080193543A1 (en) * | 2005-05-17 | 2008-08-14 | Brown University Research Foundation | Drug Delivery Formulations For Targeted Delivery |
US7823533B2 (en) | 2005-06-30 | 2010-11-02 | Advanced Cardiovascular Systems, Inc. | Stent fixture and method for reducing coating defects |
US8021676B2 (en) | 2005-07-08 | 2011-09-20 | Advanced Cardiovascular Systems, Inc. | Functionalized chemically inert polymers for coatings |
US7785647B2 (en) | 2005-07-25 | 2010-08-31 | Advanced Cardiovascular Systems, Inc. | Methods of providing antioxidants to a drug containing product |
JP2009502969A (en) * | 2005-07-28 | 2009-01-29 | アイエスピー インヴェストメンツ インコーポレイテッド | Amorphous efavirenz and its manufacture |
US7735449B1 (en) | 2005-07-28 | 2010-06-15 | Advanced Cardiovascular Systems, Inc. | Stent fixture having rounded support structures and method for use thereof |
CA2896083A1 (en) | 2005-12-08 | 2007-06-14 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
US7976891B1 (en) | 2005-12-16 | 2011-07-12 | Advanced Cardiovascular Systems, Inc. | Abluminal stent coating apparatus and method of using focused acoustic energy |
US7867547B2 (en) | 2005-12-19 | 2011-01-11 | Advanced Cardiovascular Systems, Inc. | Selectively coating luminal surfaces of stents |
US20070156230A1 (en) | 2006-01-04 | 2007-07-05 | Dugan Stephen R | Stents with radiopaque markers |
US20070207183A1 (en) * | 2006-01-05 | 2007-09-06 | Med Institute, Inc. | Zein coated medical device |
WO2007081387A1 (en) | 2006-01-11 | 2007-07-19 | Raindance Technologies, Inc. | Microfluidic devices, methods of use, and kits for performing diagnostics |
US20070196428A1 (en) | 2006-02-17 | 2007-08-23 | Thierry Glauser | Nitric oxide generating medical devices |
US7713637B2 (en) | 2006-03-03 | 2010-05-11 | Advanced Cardiovascular Systems, Inc. | Coating containing PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid polymer |
AU2007348315A1 (en) * | 2006-04-07 | 2008-09-12 | Chimeros, Inc. | Compositions and methods for treating B- cell malignancies |
US7985441B1 (en) | 2006-05-04 | 2011-07-26 | Yiwen Tang | Purification of polymers for coating applications |
US8304012B2 (en) | 2006-05-04 | 2012-11-06 | Advanced Cardiovascular Systems, Inc. | Method for drying a stent |
US8069814B2 (en) | 2006-05-04 | 2011-12-06 | Advanced Cardiovascular Systems, Inc. | Stent support devices |
US9562837B2 (en) | 2006-05-11 | 2017-02-07 | Raindance Technologies, Inc. | Systems for handling microfludic droplets |
US7775178B2 (en) | 2006-05-26 | 2010-08-17 | Advanced Cardiovascular Systems, Inc. | Stent coating apparatus and method |
US8752268B2 (en) | 2006-05-26 | 2014-06-17 | Abbott Cardiovascular Systems Inc. | Method of making stents with radiopaque markers |
US8568764B2 (en) | 2006-05-31 | 2013-10-29 | Advanced Cardiovascular Systems, Inc. | Methods of forming coating layers for medical devices utilizing flash vaporization |
US9561351B2 (en) | 2006-05-31 | 2017-02-07 | Advanced Cardiovascular Systems, Inc. | Drug delivery spiral coil construct |
US8703167B2 (en) | 2006-06-05 | 2014-04-22 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable medical devices for controlled release of a hydrophilic drug and a hydrophobic drug |
US8778376B2 (en) | 2006-06-09 | 2014-07-15 | Advanced Cardiovascular Systems, Inc. | Copolymer comprising elastin pentapeptide block and hydrophilic block, and medical device and method of treating |
US8603530B2 (en) | 2006-06-14 | 2013-12-10 | Abbott Cardiovascular Systems Inc. | Nanoshell therapy |
US20080095918A1 (en) * | 2006-06-14 | 2008-04-24 | Kleiner Lothar W | Coating construct with enhanced interfacial compatibility |
US8114150B2 (en) | 2006-06-14 | 2012-02-14 | Advanced Cardiovascular Systems, Inc. | RGD peptide attached to bioabsorbable stents |
US8048448B2 (en) | 2006-06-15 | 2011-11-01 | Abbott Cardiovascular Systems Inc. | Nanoshells for drug delivery |
US8535372B1 (en) | 2006-06-16 | 2013-09-17 | Abbott Cardiovascular Systems Inc. | Bioabsorbable stent with prohealing layer |
US8017237B2 (en) | 2006-06-23 | 2011-09-13 | Abbott Cardiovascular Systems, Inc. | Nanoshells on polymers |
US8128688B2 (en) | 2006-06-27 | 2012-03-06 | Abbott Cardiovascular Systems Inc. | Carbon coating on an implantable device |
US8956640B2 (en) * | 2006-06-29 | 2015-02-17 | Advanced Cardiovascular Systems, Inc. | Block copolymers including a methoxyethyl methacrylate midblock |
US20080008736A1 (en) * | 2006-07-06 | 2008-01-10 | Thierry Glauser | Random copolymers of methacrylates and acrylates |
US7823263B2 (en) | 2006-07-11 | 2010-11-02 | Abbott Cardiovascular Systems Inc. | Method of removing stent islands from a stent |
US9012390B2 (en) | 2006-08-07 | 2015-04-21 | Raindance Technologies, Inc. | Fluorocarbon emulsion stabilizing surfactants |
US8703169B1 (en) | 2006-08-15 | 2014-04-22 | Abbott Cardiovascular Systems Inc. | Implantable device having a coating comprising carrageenan and a biostable polymer |
US8529961B2 (en) | 2006-10-17 | 2013-09-10 | Carmell Therapeutics Corporation | Methods and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom |
WO2015081096A2 (en) | 2013-11-26 | 2015-06-04 | The Brigham And Women's Hospital, Inc. | Receptor-targeted nanoparticles for enhanced transcytosis mediated drug delivery |
US7713541B1 (en) * | 2006-11-21 | 2010-05-11 | Abbott Cardiovascular Systems Inc. | Zwitterionic terpolymers, method of making and use on medical devices |
WO2008064058A2 (en) * | 2006-11-21 | 2008-05-29 | Abbott Laboratories | Use of a terpolymer of tetrafluoroethylene, hexafluoropropylene, and vinylidene fluoride in drug eluting coatings |
US20080118541A1 (en) * | 2006-11-21 | 2008-05-22 | Abbott Laboratories | Use of a terpolymer of tetrafluoroethylene, hexafluoropropylene, and vinylidene fluoride in drug eluting coatings on medical devices |
US8597673B2 (en) | 2006-12-13 | 2013-12-03 | Advanced Cardiovascular Systems, Inc. | Coating of fast absorption or dissolution |
US8017141B2 (en) * | 2006-12-15 | 2011-09-13 | Advanced Cardiovascular Systems, Inc. | Coatings of acrylamide-based copolymers |
US10189957B2 (en) | 2007-01-26 | 2019-01-29 | Isp Investments Llc | Formulation process method to produce spray dried products |
CA2683063A1 (en) * | 2007-04-09 | 2008-10-16 | Chimeros, Inc. | Self-assembling nanoparticle drug delivery system |
US20100196455A1 (en) | 2007-05-04 | 2010-08-05 | Transave, Inc. | Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof |
US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
US9333214B2 (en) | 2007-05-07 | 2016-05-10 | Insmed Incorporated | Method for treating pulmonary disorders with liposomal amikacin formulations |
US9114081B2 (en) | 2007-05-07 | 2015-08-25 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
US20080286332A1 (en) | 2007-05-14 | 2008-11-20 | Pacetti Stephen D | Implantable medical devices with a topcoat layer of phosphoryl choline acrylate polymer for reduced thrombosis, and improved mechanical properties |
US8147769B1 (en) | 2007-05-16 | 2012-04-03 | Abbott Cardiovascular Systems Inc. | Stent and delivery system with reduced chemical degradation |
US8048441B2 (en) | 2007-06-25 | 2011-11-01 | Abbott Cardiovascular Systems, Inc. | Nanobead releasing medical devices |
US8109904B1 (en) | 2007-06-25 | 2012-02-07 | Abbott Cardiovascular Systems Inc. | Drug delivery medical devices |
US7901452B2 (en) | 2007-06-27 | 2011-03-08 | Abbott Cardiovascular Systems Inc. | Method to fabricate a stent having selected morphology to reduce restenosis |
US7955381B1 (en) | 2007-06-29 | 2011-06-07 | Advanced Cardiovascular Systems, Inc. | Polymer-bioceramic composite implantable medical device with different types of bioceramic particles |
US7960336B2 (en) | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
US8563527B2 (en) | 2007-08-20 | 2013-10-22 | Pharmain Corporation | Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same |
EP2214747A2 (en) * | 2007-11-20 | 2010-08-11 | Cook Incorporated | Controlled drug delivery using a zein layer modified with levulinic acid |
CA2709712C (en) | 2007-12-20 | 2016-05-10 | Surmodics Pharmaceuticals, Inc. | Process for preparing microparticles having a low residual solvent volume |
US8629098B2 (en) * | 2008-01-15 | 2014-01-14 | Yale University | Compositions and methods for adoptive and active immunotherapy |
US20110165248A1 (en) * | 2008-09-18 | 2011-07-07 | Meridith Lee Machonis | Pharmaceutical dosage forms comprising poly(e-caprolactone) |
EP2364168A1 (en) | 2008-12-04 | 2011-09-14 | Botulinum Toxin Research Associates, Inc. | Extended length botulinum toxin formulation for human or mammalian use |
WO2010120874A2 (en) | 2009-04-14 | 2010-10-21 | Chimeros, Inc. | Chimeric therapeutics, compositions, and methods for using same |
CN102497886B (en) | 2009-07-21 | 2016-01-20 | 玛丽皇后与斯特菲尔德学院 | For Fas (Apo-1, CD95) the targeting platform that Intracellular drug is sent |
US8568471B2 (en) | 2010-01-30 | 2013-10-29 | Abbott Cardiovascular Systems Inc. | Crush recoverable polymer scaffolds |
US8808353B2 (en) | 2010-01-30 | 2014-08-19 | Abbott Cardiovascular Systems Inc. | Crush recoverable polymer scaffolds having a low crossing profile |
US9366632B2 (en) | 2010-02-12 | 2016-06-14 | Raindance Technologies, Inc. | Digital analyte analysis |
US8895597B2 (en) | 2010-06-17 | 2014-11-25 | Violette Renard Recinos | Combination of local temozolomide with local BCNU |
US8673359B2 (en) | 2010-07-08 | 2014-03-18 | Brown University | Nanoparticle compositions and methods for improved oral delivery of active agents |
US8841071B2 (en) | 2011-06-02 | 2014-09-23 | Raindance Technologies, Inc. | Sample multiplexing |
US8726483B2 (en) | 2011-07-29 | 2014-05-20 | Abbott Cardiovascular Systems Inc. | Methods for uniform crimping and deployment of a polymer scaffold |
EP2747774A4 (en) | 2011-09-09 | 2015-02-11 | Biomed Realty L P | Methods and compositions for controlling assembly of viral proteins |
WO2013063383A2 (en) | 2011-10-27 | 2013-05-02 | Wellstat Ophthalmics Corporation | Vectors encoding rod-derived cone viability factor |
US9394547B2 (en) | 2012-01-03 | 2016-07-19 | City University Of Hong Kong | Method and apparatus for delivery of molecules to cells |
WO2013123492A2 (en) | 2012-02-17 | 2013-08-22 | Massachusetts Institute Of Technology | Glucose-responsive microgels for closed loop insulin delivery |
US9393291B2 (en) | 2012-04-12 | 2016-07-19 | Botulinum Toxin Research Associates, Inc. | Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds |
CA2870860C (en) | 2012-05-21 | 2021-07-27 | Insmed Incorporated | Systems for treating pulmonary infections |
US9526884B2 (en) | 2012-11-16 | 2016-12-27 | City University Of Hong Kong | Mechanically robust fast-dissolving microneedles for transdermal drug and vaccine delivery |
RU2675859C2 (en) | 2012-11-29 | 2018-12-25 | Инсмед Инкорпорейтед | Stabilised vancomycin formulations |
DE102013004595A1 (en) | 2013-03-15 | 2014-09-18 | Emergent Product Development Germany Gmbh | RSV vaccines |
BR112016006192A2 (en) | 2013-09-25 | 2017-09-26 | Zoetis Services Llc | pcv2b divergent vaccine composition and methods of use |
US9649279B2 (en) | 2013-12-16 | 2017-05-16 | Massachusetts Institute Of Technology | Fortified micronutrient salt formulations |
EP3092040B1 (en) | 2014-01-10 | 2019-07-17 | Chamber Works, LLC | A personalizing substance for application to the skin or addition to tattoo ink and methods of preparation thereof |
ES2926985T3 (en) | 2014-05-15 | 2022-10-31 | Insmed Inc | Methods for treating nontuberculous mycobacterial lung infections |
US9381280B2 (en) | 2014-06-13 | 2016-07-05 | Abbott Cardiovascular Systems Inc. | Plasticizers for a biodegradable scaffolding and methods of forming same |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
US9901627B2 (en) | 2014-07-18 | 2018-02-27 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
AU2015301399B2 (en) | 2014-08-14 | 2018-11-08 | Brown University | Compositions for stabilizing and delivering proteins |
WO2016077215A2 (en) | 2014-11-10 | 2016-05-19 | Yale University | Modular nanodevices for smart adaptable vaccines |
US9999527B2 (en) | 2015-02-11 | 2018-06-19 | Abbott Cardiovascular Systems Inc. | Scaffolds having radiopaque markers |
EP3256129A1 (en) | 2015-02-11 | 2017-12-20 | The Johns Hopkins University | Local delivery forms of acriflavine for treating tumors |
US9700443B2 (en) | 2015-06-12 | 2017-07-11 | Abbott Cardiovascular Systems Inc. | Methods for attaching a radiopaque marker to a scaffold |
US10363226B2 (en) | 2015-08-12 | 2019-07-30 | North Carolina State University | Platelet membrane-coated drug delivery system |
CA3036693A1 (en) | 2016-09-13 | 2018-03-22 | North Carolina State University | Platelet compositions and methods for the delivery of therapeutic agents |
WO2019136160A1 (en) | 2018-01-04 | 2019-07-11 | Massachusetts Institute Of Technology | Water- and fat-soluble micronutient-stabilised particles with an enteric polymer barrier |
WO2019191627A1 (en) | 2018-03-30 | 2019-10-03 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
CN111989068A (en) * | 2018-05-24 | 2020-11-24 | 塞拉尼斯伊娃高性能聚合物公司 | Implantable devices for sustained release of macromolecular drug compounds |
US11690807B2 (en) | 2018-05-24 | 2023-07-04 | Celanese Eva Performance Polymers Llc | Implantable device for sustained release of a macromolecular drug compound |
WO2020028907A1 (en) | 2018-08-03 | 2020-02-06 | Brown University | Compositions and methods for improving the bioavailability of glp1 and analogues thereof |
US20220313725A1 (en) * | 2021-03-30 | 2022-10-06 | Celanese Eva Performance Polymers Llc | Implantable Medical Device for the Delivery of a Nucleic Acid |
US20230233691A1 (en) | 2021-10-22 | 2023-07-27 | University Of Houston System | Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5100669A (en) * | 1988-02-24 | 1992-03-31 | Biomaterials Universe, Inc. | Polylactic acid type microspheres containing physiologically active substance and process for preparing the same |
WO1993008850A1 (en) * | 1991-10-30 | 1993-05-13 | Massachusetts Institute Of Technology | Prevascularized polymeric implants for organ transplantation |
WO1993025221A1 (en) * | 1992-06-11 | 1993-12-23 | Alkermes Controlled Therapeutics, Inc. | Erythropoietin drug delivery system |
EP0579347A1 (en) * | 1992-07-10 | 1994-01-19 | FERRING ARZNEIMITTEL GmbH | Microencapsulation of water-soluble drugs |
WO1994023738A1 (en) * | 1993-04-19 | 1994-10-27 | Medisorb Technologies International L.P. | Encapsulation of nucleic acids with conjugates that facilitate and target cellular uptake and gene expression |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4272398A (en) | 1978-08-17 | 1981-06-09 | The United States Of America As Represented By The Secretary Of Agriculture | Microencapsulation process |
US5100792A (en) | 1984-11-13 | 1992-03-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4775624A (en) | 1985-02-08 | 1988-10-04 | Eli Lilly And Company | Vectors and compounds for expression of human protein C |
US4863735A (en) * | 1985-02-19 | 1989-09-05 | Massachusetts Institute Of Technology | Biodegradable polymeric drug delivery system with adjuvant activity |
EP0248531A3 (en) * | 1986-05-02 | 1988-09-28 | Southern Research Institute | Encapsulated nucleic acids |
US5811128A (en) * | 1986-10-24 | 1998-09-22 | Southern Research Institute | Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor |
US4861627A (en) | 1987-05-01 | 1989-08-29 | Massachusetts Institute Of Technology | Preparation of multiwall polymeric microcapsules |
US4897268A (en) * | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
US4898734A (en) | 1988-02-29 | 1990-02-06 | Massachusetts Institute Of Technology | Polymer composite for controlled release or membrane formation |
US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
US5674192A (en) * | 1990-12-28 | 1997-10-07 | Boston Scientific Corporation | Drug delivery |
US5171217A (en) | 1991-02-28 | 1992-12-15 | Indiana University Foundation | Method for delivery of smooth muscle cell inhibitors |
US5643578A (en) * | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
US5792751A (en) * | 1992-04-13 | 1998-08-11 | Baylor College Of Medicine | Tranformation of cells associated with fluid spaces |
US6197346B1 (en) * | 1992-04-24 | 2001-03-06 | Brown Universtiy Research Foundation | Bioadhesive microspheres and their use as drug delivery and imaging systems |
EP0671926B1 (en) * | 1992-08-11 | 2002-11-13 | President And Fellows Of Harvard College | Immunomodulatory peptides |
WO1994018954A1 (en) * | 1993-02-22 | 1994-09-01 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of biologics and compositions useful therefor |
US5366881A (en) | 1993-02-23 | 1994-11-22 | The United States Of America As Represented By The Secretary Of The Navy | Polymerizable lipids for preparing vesicles that controllably release an encapsulant |
US5763416A (en) * | 1994-02-18 | 1998-06-09 | The Regent Of The University Of Michigan | Gene transfer into bone cells and tissues |
US5783567A (en) * | 1997-01-22 | 1998-07-21 | Pangaea Pharmaceuticals, Inc. | Microparticles for delivery of nucleic acid |
-
1995
- 1995-03-15 AU AU21214/95A patent/AU710504B2/en not_active Ceased
- 1995-03-15 EP EP95914073A patent/EP0804249A2/en not_active Withdrawn
- 1995-03-15 WO PCT/US1995/003307 patent/WO1995024929A2/en not_active Application Discontinuation
- 1995-03-15 CA CA002190121A patent/CA2190121A1/en not_active Abandoned
-
1997
- 1997-11-25 US US08/978,522 patent/US6262034B1/en not_active Expired - Fee Related
-
1998
- 1998-10-15 US US09/173,205 patent/US6475779B2/en not_active Expired - Fee Related
-
2001
- 2001-03-23 US US09/815,807 patent/US6620617B2/en not_active Expired - Fee Related
-
2003
- 2003-09-16 US US10/663,265 patent/US20040126884A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5100669A (en) * | 1988-02-24 | 1992-03-31 | Biomaterials Universe, Inc. | Polylactic acid type microspheres containing physiologically active substance and process for preparing the same |
WO1993008850A1 (en) * | 1991-10-30 | 1993-05-13 | Massachusetts Institute Of Technology | Prevascularized polymeric implants for organ transplantation |
WO1993025221A1 (en) * | 1992-06-11 | 1993-12-23 | Alkermes Controlled Therapeutics, Inc. | Erythropoietin drug delivery system |
EP0579347A1 (en) * | 1992-07-10 | 1994-01-19 | FERRING ARZNEIMITTEL GmbH | Microencapsulation of water-soluble drugs |
WO1994023738A1 (en) * | 1993-04-19 | 1994-10-27 | Medisorb Technologies International L.P. | Encapsulation of nucleic acids with conjugates that facilitate and target cellular uptake and gene expression |
Non-Patent Citations (2)
Title |
---|
FASEB JOURNAL FOR EXPERIMENTAL BIOLOGY, vol.7, no.11, , BETHESDA, MD US pages 1061 - 1069 I.T. TAI ET AL. 'Microencapsulation of recombinant cells: a new delivery system for gene therapy' * |
PROC. NATL. ACAD. SCI. USA, vol.90, 3 pages 11307 - 11311 G. NABEL ET AL. 'Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans' cited in the application * |
Cited By (258)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6511957B1 (en) | 1993-02-19 | 2003-01-28 | Howard Green | Compositions containing corneocyte proteins |
US6551618B2 (en) * | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
US7674777B2 (en) | 1994-07-15 | 2010-03-09 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US8158592B2 (en) | 1994-07-15 | 2012-04-17 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acid molecules |
US8148340B2 (en) | 1994-07-15 | 2012-04-03 | The United States Of America As Represented By The Department Of Health And Human Services | Immunomodulatory oligonucleotides |
WO1996005321A1 (en) * | 1994-08-17 | 1996-02-22 | Rhone-Poulenc Rorer S.A. | Gene therapy for restenosis using an adenoviral vector |
US6514947B2 (en) | 1995-01-13 | 2003-02-04 | Valentis, Inc. | Formulated nucleic acid compositions and methods of administering the same for gene therapy |
EP0844004A4 (en) * | 1995-07-03 | 2000-03-15 | Koken Kk | Gene preparations |
EP0844004A1 (en) * | 1995-07-03 | 1998-05-27 | Koken Company Limited | Gene preparations |
US6998268B2 (en) | 1995-07-03 | 2006-02-14 | Dainippon Sumitomo Pharma Co. Ltd. | Gene preparations |
US6616869B2 (en) | 1995-07-21 | 2003-09-09 | Brown University Research Foundation | Process for preparing microparticles through phase inversion phenomena |
US6677313B1 (en) | 1995-07-21 | 2004-01-13 | Brown University Research Foundation | Method for gene therapy using nucleic acid loaded polymeric microparticles |
WO1997003702A1 (en) * | 1995-07-21 | 1997-02-06 | Brown University Research Foundation | A method for gene therapy using nucleic acid loaded polymeric microparticles |
US6143211A (en) * | 1995-07-21 | 2000-11-07 | Brown University Foundation | Process for preparing microparticles through phase inversion phenomena |
JP2010047620A (en) * | 1995-11-09 | 2010-03-04 | Health Protection Agency | Microencapsulated dna for vaccination and gene therapy |
WO1997017063A1 (en) * | 1995-11-09 | 1997-05-15 | Microbiological Research Authority | Microencapsulated dna for vaccination and gene therapy |
AU717113B2 (en) * | 1995-11-09 | 2000-03-16 | Health Protection Agency | Microencapsulated DNA for vaccination and gene therapy |
EP0965336A1 (en) * | 1995-11-09 | 1999-12-22 | Microbiological Research Authority | Microencapsulated DNA for gene therapy |
US6270795B1 (en) | 1995-11-09 | 2001-08-07 | Microbiological Research Authority | Method of making microencapsulated DNA for vaccination and gene therapy |
JP2000500744A (en) * | 1995-11-09 | 2000-01-25 | マイクロバイオロジカル リサーチ オーソリティー | Microencapsulated DNA for vaccination and gene therapy |
US6667294B2 (en) | 1995-11-09 | 2003-12-23 | Microbiological Research Authority | Microencapsulated DNA for vaccination and gene therapy |
US6004943A (en) * | 1995-11-27 | 1999-12-21 | Inst. Of Biomedical Engineering, Chinese Acdmy Of Med. Science | Protein-coated medical substrates for local delivery of genes and method of forming coatings on the substrates |
US6027721A (en) * | 1996-05-20 | 2000-02-22 | Cytotherapeutics, Inc. | Device and method for encapsulated gene therapy |
US6143037A (en) * | 1996-06-12 | 2000-11-07 | The Regents Of The University Of Michigan | Compositions and methods for coating medical devices |
US6248720B1 (en) | 1996-07-03 | 2001-06-19 | Brown University Research Foundation | Method for gene therapy using nucleic acid loaded polymeric microparticles |
US7112442B2 (en) | 1996-11-04 | 2006-09-26 | The Regents Of The University Of Michigan | Peptides for gene delivery |
WO1998051279A3 (en) * | 1996-11-12 | 1999-02-18 | Microbiological Res Authority | Method of making microencapsulated dna for vaccination and gene therapy |
WO1998051279A2 (en) * | 1996-11-12 | 1998-11-19 | Microbiological Research Authority | Method of making microencapsulated dna for vaccination and gene therapy |
US5783567A (en) * | 1997-01-22 | 1998-07-21 | Pangaea Pharmaceuticals, Inc. | Microparticles for delivery of nucleic acid |
EP1005374A1 (en) * | 1997-01-22 | 2000-06-07 | Zycos Inc. | Microparticles for delivery of nucleic acid |
JP2001509178A (en) * | 1997-01-22 | 2001-07-10 | ザイコス インク. | Microparticles for transporting nucleic acids |
EP1837017A2 (en) * | 1997-01-22 | 2007-09-26 | MGI PHARMA Biologics, Inc. | Microparticles for delivery of nucleic acid |
EP1837017A3 (en) * | 1997-01-22 | 2009-12-23 | Eisai Inc. | Microparticles for delivery of nucleic acid |
EP1005374A4 (en) * | 1997-01-22 | 2002-08-28 | Zycos Inc | Microparticles for delivery of nucleic acid |
JP2009261411A (en) * | 1997-01-22 | 2009-11-12 | Eisai Corp Of North America | Microparticle for delivering nucleic acid |
US6884435B1 (en) * | 1997-01-30 | 2005-04-26 | Chiron Corporation | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
US7597908B2 (en) | 1997-01-30 | 2009-10-06 | Novartis Vaccines And Diagnostics, Inc. | Use of microparticles with adsorbed antigen to stimulate immune responses |
EP2042599A1 (en) * | 1997-05-15 | 2009-04-01 | Health Protection Agency | Method of making microencapsulated DNA for vaccination and gene therapy |
US9528106B2 (en) | 1997-07-07 | 2016-12-27 | Medical Research Council | In vitro sorting method |
US8367326B2 (en) | 1997-07-07 | 2013-02-05 | Medical Research Council | In vitro sorting method |
US7582446B2 (en) | 1997-07-07 | 2009-09-01 | Medical Research Council | In vitro sorting method |
US7138233B2 (en) | 1997-07-07 | 2006-11-21 | Medical Research Council | IN vitro sorting method |
US7638276B2 (en) | 1997-07-07 | 2009-12-29 | 454 Life Sciences Corporation | In vitro sorting method |
US7252943B2 (en) | 1997-07-07 | 2007-08-07 | Medical Research Council | In Vitro sorting method |
US6013258A (en) * | 1997-10-09 | 2000-01-11 | Zycos Inc. | Immunogenic peptides from the HPV E7 protein |
US7097843B2 (en) | 1997-10-09 | 2006-08-29 | Mgi Pharma Biologics, Inc. | Immunogenic peptides from the HPV E7 protein |
US6183746B1 (en) | 1997-10-09 | 2001-02-06 | Zycos Inc. | Immunogenic peptides from the HPV E7 protein |
US6582704B2 (en) | 1997-10-09 | 2003-06-24 | Zycos Inc. | Immunogenic peptides from the HPV E7 protein |
WO1999029304A1 (en) * | 1997-12-12 | 1999-06-17 | Massachusetts Institute Of Technology | Method for high supercoiled dna content microspheres |
US6197229B1 (en) * | 1997-12-12 | 2001-03-06 | Massachusetts Institute Of Technology | Method for high supercoiled DNA content microspheres |
US6267957B1 (en) | 1998-01-20 | 2001-07-31 | Howard Green | Attaching agents to tissue with transglutaminase and a transglutaminase substrate |
US6395253B2 (en) | 1998-04-23 | 2002-05-28 | The Regents Of The University Of Michigan | Microspheres containing condensed polyanionic bioactive agents and methods for their production |
US6379379B1 (en) | 1998-05-05 | 2002-04-30 | Scimed Life Systems, Inc. | Stent with smooth ends |
US6406719B1 (en) | 1998-05-13 | 2002-06-18 | Microbiological Research Authority | Encapsulation of bioactive agents |
US6565777B2 (en) | 1998-05-13 | 2003-05-20 | Microbiological Research Authority | Encapsulation of bioactive agents |
US6309569B1 (en) | 1998-05-13 | 2001-10-30 | Microbiological Research Authority | Encapsulation of bioactive agents |
US8574599B1 (en) | 1998-05-22 | 2013-11-05 | Ottawa Hospital Research Institute | Methods and products for inducing mucosal immunity |
WO1999066959A2 (en) * | 1998-06-01 | 1999-12-29 | Selective Genetics, Inc. | Compositions and methods for delivery of genetic material for altering neuronal growth, regeneration, and survival |
WO1999066959A3 (en) * | 1998-06-01 | 2000-05-04 | Selective Genetics Inc | Compositions and methods for delivery of genetic material for altering neuronal growth, regeneration, and survival |
WO1999065463A1 (en) * | 1998-06-16 | 1999-12-23 | Ben-Gurion University Of The Negev | Active ingredient delivery systems and devices based on porous matrices |
US6548302B1 (en) | 1998-06-18 | 2003-04-15 | Johns Hopkins University School Of Medicine | Polymers for delivery of nucleic acids |
EP1098667A4 (en) * | 1998-07-17 | 2002-09-11 | Mirus Corp | Chelating systems for use in the delivery of compounds to cells |
EP1098667A1 (en) * | 1998-07-17 | 2001-05-16 | Mirus Corporation | Chelating systems for use in the delivery of compounds to cells |
WO2000003738A1 (en) * | 1998-07-17 | 2000-01-27 | Mirus Corporation | Chelating systems for use in the delivery of compounds to cells |
US6916490B1 (en) | 1998-07-23 | 2005-07-12 | UAB Research Center | Controlled release of bioactive substances |
EP1208212A1 (en) * | 1999-06-16 | 2002-05-29 | Bristol-Myers Squibb Company | Fibrin sealant as a transfection/transformation vehicle for gene therapy |
EP1208212A4 (en) * | 1999-06-16 | 2007-05-02 | Bristol Myers Squibb Co | Fibrin sealant as a transfection/transformation vehicle for gene therapy |
US6770740B1 (en) | 1999-07-13 | 2004-08-03 | The Regents Of The University Of Michigan | Crosslinked DNA condensate compositions and gene delivery methods |
EP2267029A2 (en) | 1999-09-03 | 2010-12-29 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of inflammatory disease using Cadherin-11 modulating agents |
EP2100620A1 (en) | 1999-09-16 | 2009-09-16 | Eisai Corporation of North America | Nucleic acids encoding polyepitope polypeptides |
US7491537B2 (en) | 2000-03-03 | 2009-02-17 | Genetronics Biomedical Corporation | Nucleic acid formulations for gene delivery and methods of use |
US7173116B2 (en) | 2000-03-03 | 2007-02-06 | Genetronics Biomedical Corporation | Nucleic acid formulations for gene delivery and methods of use |
WO2001074413A1 (en) * | 2000-04-04 | 2001-10-11 | Boston Scientific Limited | Medical devices suitable for gene therapy regimens |
AU2001238518B2 (en) * | 2000-04-04 | 2006-09-07 | Boston Scientific Limited | Medical devices suitable for gene therapy regimens |
US7846479B2 (en) | 2000-09-28 | 2010-12-07 | Novartis Vaccines And Diagnostics, Inc. | Microparticle compositions and methods for the manufacture thereof |
US6753015B2 (en) | 2000-09-28 | 2004-06-22 | Chiron Corporation | Microparticle compositions and methods for the manufacture thereof |
KR20020028419A (en) * | 2000-10-10 | 2002-04-17 | 서만석 | A method of transmitting plasmid, DNA or DNA vaccination |
EP2295578A2 (en) | 2000-10-31 | 2011-03-16 | Eisai Inc. | Cyp1b1 nucleic acids and methods of use |
WO2002042325A2 (en) | 2000-10-31 | 2002-05-30 | Zycos Inc. | Cyp1b1 nucleic acids and methods of use |
US6518308B2 (en) | 2000-11-21 | 2003-02-11 | Michael P. Diamond | Compositions for adhesion prevention |
US7700715B2 (en) | 2000-11-27 | 2010-04-20 | Minerva Biotechnologies Corporation | Diagnostic tumor markers, drug screening for tumorigenesis inhibition, and compositions and methods for treatment of cancer |
EP2386859A2 (en) | 2000-11-27 | 2011-11-16 | Minerva Biotechnologies Corporation | Diagnostic tumor markers |
US8344113B2 (en) | 2000-11-27 | 2013-01-01 | Minerva Biotechnologies Corporation | Diagnostic tumor markers, drug screening for tumorigenesis inhibition, and compositions and methods for treatment of cancer |
EP2241887A2 (en) | 2000-11-27 | 2010-10-20 | Minerva Biotechnologies Corporation | Diagnostics, drug screening and treatment for cancer |
WO2002058752A3 (en) * | 2000-12-04 | 2002-11-21 | Medtronic Inc | Medical device and methods of use |
WO2002058752A2 (en) * | 2000-12-04 | 2002-08-01 | Medtronic, Inc. | Medical device and methods of use |
US10064982B2 (en) | 2001-06-27 | 2018-09-04 | Abbott Cardiovascular Systems Inc. | PDLLA stent coating |
US8524829B2 (en) | 2001-08-08 | 2013-09-03 | Brown University Research Foundation | Methods for micronization of hydrophobic drugs |
WO2003044187A2 (en) * | 2001-11-16 | 2003-05-30 | Medical Research Council | Emulsion compositions |
US7622280B2 (en) | 2001-11-16 | 2009-11-24 | 454 Life Sciences Corporation | Emulsion compositions |
US7429467B2 (en) | 2001-11-16 | 2008-09-30 | Medical Research Council | Emulsion compositions |
WO2003044187A3 (en) * | 2001-11-16 | 2003-09-04 | Medical Res Council | Emulsion compositions |
US8153402B2 (en) | 2001-11-16 | 2012-04-10 | Medical Research Council | Emulsion compositions |
US8153364B2 (en) | 2001-11-16 | 2012-04-10 | Mrc | Emulsion compositions |
EP1518937A1 (en) * | 2001-11-16 | 2005-03-30 | Medical Research Council | Increasing the concentration of a nucleic acid molecule |
WO2003055411A3 (en) * | 2001-12-28 | 2004-02-19 | Nmi Univ Tuebingen | Implantable device and the use thereof |
WO2003055411A2 (en) * | 2001-12-28 | 2003-07-10 | NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen | Implantable device and the use thereof |
EP3006043A1 (en) | 2002-04-04 | 2016-04-13 | Zoetis Belgium S.A. | Immunostimulatory g,u-containing oligoribonucleotides |
EP3425059A1 (en) | 2002-05-09 | 2019-01-09 | The Brigham and Women's Hospital, Inc. | 1l1rl-1 as a cardiovascular disease marker |
EP3072978A1 (en) | 2002-05-09 | 2016-09-28 | The Brigham and Women's Hospital, Inc. | 1l1rl-1 as a cardiovascular disease marker and therapeutic target |
EP2336359A1 (en) | 2002-05-09 | 2011-06-22 | The Brigham and Women's Hospital, Inc. | 1L1RL-1 as a cardiovascular disease marker and therapeutic target |
US9084671B2 (en) | 2002-06-21 | 2015-07-21 | Advanced Cardiovascular Systems, Inc. | Methods of forming a micronized peptide coated stent |
WO2004037175A2 (en) | 2002-10-21 | 2004-05-06 | Mgi Pharma Biologics, Inc. | Compositions and methods for treating human papillomavirus-mediated disease |
EP2363410A1 (en) | 2002-11-27 | 2011-09-07 | Minerva Biotechnologies Corporation | Isoforms of MUC1 |
US10982274B2 (en) | 2003-01-29 | 2021-04-20 | Roche Molecular Systems, Inc. | Bead emulsion nucleic acid amplification |
US10240192B2 (en) | 2003-01-29 | 2019-03-26 | 454 Life Sciences Corporation | Bead emulsion nucleic acid amplification |
US8748102B2 (en) | 2003-01-29 | 2014-06-10 | 454 Life Sciences Corporation | Bead emulsion nucleic acid amplification |
US7842457B2 (en) | 2003-01-29 | 2010-11-30 | 454 Life Sciences Corporation | Bead emulsion nucleic acid amplification |
US8765380B2 (en) | 2003-01-29 | 2014-07-01 | 454 Life Sciences Corporation | Bead emulsion nucleic acid amplification |
US8012690B2 (en) | 2003-01-29 | 2011-09-06 | 454 Life Sciences Corporation | Bead emulsion nucleic acid amplification |
EP2325302A1 (en) | 2003-02-11 | 2011-05-25 | Shire Human Genetic Therapies, Inc. | Diagnosis and treatment of multiple sulfatase deficiency and others using a formylglycine generating enzyme (FGE) |
EP2325301A1 (en) | 2003-02-11 | 2011-05-25 | Shire Human Genetic Therapies, Inc. | Diagnosis and treatment of multiple sulfatase deficiency and others using a formylglycine generating enzyme (FGE) |
US11187702B2 (en) | 2003-03-14 | 2021-11-30 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
US9857303B2 (en) | 2003-03-31 | 2018-01-02 | Medical Research Council | Selection by compartmentalised screening |
US10052605B2 (en) | 2003-03-31 | 2018-08-21 | Medical Research Council | Method of synthesis and testing of combinatorial libraries using microcapsules |
US9175162B2 (en) | 2003-05-08 | 2015-11-03 | Advanced Cardiovascular Systems, Inc. | Methods for forming stent coatings comprising hydrophilic additives |
EP2058329A1 (en) | 2003-06-10 | 2009-05-13 | NsGene A/S | Improved secretion of neublastin |
EP2377528A2 (en) | 2003-06-12 | 2011-10-19 | The Board of Regents of the University of Colorado | Fatty acid metabolism inhibitors for use in the treatment of cancer |
US9328343B2 (en) | 2003-07-05 | 2016-05-03 | The Johns Hopkins University | Method and compositions for detection and enumeration of genetic variations |
US8048627B2 (en) | 2003-07-05 | 2011-11-01 | The Johns Hopkins University | Method and compositions for detection and enumeration of genetic variations |
US10604797B2 (en) | 2003-07-05 | 2020-03-31 | The Johns Hopkins University | Method and compositions for detection and enumeration of genetic variations |
EP2210617A1 (en) | 2003-10-20 | 2010-07-28 | NsGene A/S | Mammalian cells secreting Neurturin and their therapeutic use |
EP2075254A1 (en) | 2004-03-30 | 2009-07-01 | NsGene A/S | Therapeutic use of a growth factor, NsG33 |
EP2289911A2 (en) | 2004-03-30 | 2011-03-02 | NsGene A/S | Therapeutic use of a growth factor, NsG33 |
US9925504B2 (en) | 2004-03-31 | 2018-03-27 | President And Fellows Of Harvard College | Compartmentalised combinatorial chemistry by microfluidic control |
US9839890B2 (en) | 2004-03-31 | 2017-12-12 | National Science Foundation | Compartmentalised combinatorial chemistry by microfluidic control |
US11821109B2 (en) | 2004-03-31 | 2023-11-21 | President And Fellows Of Harvard College | Compartmentalised combinatorial chemistry by microfluidic control |
EP2455402A1 (en) | 2004-04-21 | 2012-05-23 | The Brigham and Women's Hospital, Inc. | Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof |
EP2468769A1 (en) | 2004-04-21 | 2012-06-27 | The Brigham and Women's Hospital, Inc. | Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof |
EP2455400A1 (en) | 2004-04-21 | 2012-05-23 | The Brigham and Women's Hospital, Inc. | Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof |
EP2455401A1 (en) | 2004-04-21 | 2012-05-23 | The Brigham and Women's Hospital, Inc. | Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof |
EP2439213A1 (en) | 2004-04-21 | 2012-04-11 | The Brigham and Women's Hospital, Inc. | Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof |
US9375445B2 (en) | 2004-06-18 | 2016-06-28 | Abbott Cardiovascular Systems Inc. | Heparin prodrugs and drug delivery stents formed therefrom |
US9580558B2 (en) | 2004-07-30 | 2017-02-28 | Abbott Cardiovascular Systems Inc. | Polymers containing siloxane monomers |
WO2006023603A2 (en) | 2004-08-17 | 2006-03-02 | The Johns Hopkins University | Pde5 inhibitor compositions and methods for treating cardiac indications |
US8119153B2 (en) | 2004-08-26 | 2012-02-21 | Boston Scientific Scimed, Inc. | Stents with drug eluting coatings |
US11786872B2 (en) | 2004-10-08 | 2023-10-17 | United Kingdom Research And Innovation | Vitro evolution in microfluidic systems |
US9029083B2 (en) | 2004-10-08 | 2015-05-12 | Medical Research Council | Vitro evolution in microfluidic systems |
US9067000B2 (en) | 2004-10-27 | 2015-06-30 | Abbott Cardiovascular Systems Inc. | End-capped poly(ester amide) copolymers |
WO2006105448A2 (en) | 2005-03-30 | 2006-10-05 | Minerva Biotechnologies Corporation | Proliferation of muc1 expressing cells |
EP2526957A2 (en) | 2005-03-30 | 2012-11-28 | Minerva Biotechnologies Corporation | Proliferation of MUC1 expressing cells |
EP2527365A2 (en) | 2005-03-30 | 2012-11-28 | Minerva Biotechnologies Corporation | Proliferation of MUC1 expressing cells |
US10703821B2 (en) | 2005-03-30 | 2020-07-07 | Minerva Biotechnologies Corporation | Method for stimulating or enhancing proliferation of cells by activating the mucin 1 (MUC1) receptor |
US8859495B2 (en) | 2005-03-30 | 2014-10-14 | Minerva Biotechnologies Corporation | Methods for stimulating or enhancing proliferation of non-tumorous cells expressing MUC1 receptors |
US7838502B2 (en) | 2005-05-06 | 2010-11-23 | University Of Massachusetts Medical School | Compositions and methods to modulate H. influenzae pathogenesis |
EP2374451A2 (en) | 2005-07-27 | 2011-10-12 | University of Florida Research Foundation, Inc. | Histone deacetylase inhibitors (HDAC) that correct protein misfolding and uses thereof |
WO2007027559A2 (en) | 2005-08-29 | 2007-03-08 | Shashoua Victor E | Neuroprotective and neurorestorative methods and compositions |
WO2007062107A2 (en) | 2005-11-25 | 2007-05-31 | Coley Pharmaceutical Gmbh | Immunostimulatory oligoribonucleotides |
EP2883957A1 (en) | 2005-11-25 | 2015-06-17 | Zoetis Belgium S.A. | Immunostimmulatory oligoribonucleotides |
US8481068B2 (en) | 2005-12-14 | 2013-07-09 | The Invention Science Fund I, Llc | Bone cell delivery device |
US9023630B2 (en) | 2005-12-14 | 2015-05-05 | The Invention Science Fund I, Llc | Bone cell delivery device |
US8354258B2 (en) | 2005-12-14 | 2013-01-15 | The Invention Science Fund I, Llc | Diatom device |
US8999711B2 (en) | 2005-12-14 | 2015-04-07 | The Invention Science Fund I, Llc | Bone delivery device |
US9005944B2 (en) | 2005-12-14 | 2015-04-14 | The Invention Science Fund I, Llc | Bone cell delivery device |
US9005943B2 (en) | 2005-12-14 | 2015-04-14 | The Invention Science Fund I, Llc | Bone cell delivery device |
US8900865B2 (en) | 2005-12-14 | 2014-12-02 | The Invention Science Fund I, Llc | Blood brain barrier device |
US8906687B2 (en) | 2005-12-14 | 2014-12-09 | The Invention Science Fund I, Llc | Blood brain barrier device |
US8975074B2 (en) | 2005-12-14 | 2015-03-10 | The Invention Science Fund I, Llc | Bone semi-permeable device |
US8691545B2 (en) | 2005-12-14 | 2014-04-08 | The Invention Science Fund I, Llc | Bone semi-permeable device |
US8492143B2 (en) | 2005-12-14 | 2013-07-23 | The Invention Science Fund I, Llc | Bone delivery device |
US8962316B2 (en) | 2005-12-14 | 2015-02-24 | The Invention Science Fund I, Llc | Choroid plexus device |
US9061075B2 (en) | 2005-12-14 | 2015-06-23 | The Invention Science Fund I, Llc | Bone delivery device |
US11351510B2 (en) | 2006-05-11 | 2022-06-07 | Bio-Rad Laboratories, Inc. | Microfluidic devices |
US9028859B2 (en) | 2006-07-07 | 2015-05-12 | Advanced Cardiovascular Systems, Inc. | Phase-separated block copolymer coatings for implantable medical devices |
US11819849B2 (en) | 2007-02-06 | 2023-11-21 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
US10603662B2 (en) | 2007-02-06 | 2020-03-31 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
US9017623B2 (en) | 2007-02-06 | 2015-04-28 | Raindance Technologies, Inc. | Manipulation of fluids and reactions in microfluidic systems |
EP2644205A1 (en) | 2007-04-12 | 2013-10-02 | The Brigham and Women's Hospital, Inc. | Targeting ABCB5 for cancer therapy |
EP3431103A1 (en) | 2007-04-12 | 2019-01-23 | The Brigham and Women's Hospital, Inc. | Targeting abcb5 for cancer therapy |
US10960397B2 (en) | 2007-04-19 | 2021-03-30 | President And Fellows Of Harvard College | Manipulation of fluids, fluid components and reactions in microfluidic systems |
US10357772B2 (en) | 2007-04-19 | 2019-07-23 | President And Fellows Of Harvard College | Manipulation of fluids, fluid components and reactions in microfluidic systems |
US11618024B2 (en) | 2007-04-19 | 2023-04-04 | President And Fellows Of Harvard College | Manipulation of fluids, fluid components and reactions in microfluidic systems |
US9068699B2 (en) | 2007-04-19 | 2015-06-30 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
US10675626B2 (en) | 2007-04-19 | 2020-06-09 | President And Fellows Of Harvard College | Manipulation of fluids, fluid components and reactions in microfluidic systems |
US11224876B2 (en) | 2007-04-19 | 2022-01-18 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
US9200287B2 (en) | 2007-05-18 | 2015-12-01 | Adiutide Pharmaceuticals Gmbh | Phosphate-modified oligonucleotide analogs with enhanced immunostimulatory activity |
US9056155B1 (en) | 2007-05-29 | 2015-06-16 | Abbott Cardiovascular Systems Inc. | Coatings having an elastic primer layer |
US8993718B2 (en) | 2007-06-15 | 2015-03-31 | President And Fellows Of Harvard College | Methods and compositions for detecting and modulating O-glycosylation |
US8524444B2 (en) | 2007-06-15 | 2013-09-03 | President And Fellows Of Harvard College | Methods and compositions for detections and modulating O-glycosylation |
EP2385370A1 (en) | 2008-04-10 | 2011-11-09 | Massachusetts Institute of Technology (MIT) | Methods for identification and use of agents targeting cancer stem cells |
EP2910637A1 (en) | 2008-05-20 | 2015-08-26 | University of Florida Research Foundation, Inc. | Vectors for delivery of light-sensitive proteins and methods of use |
US10426844B2 (en) | 2008-05-20 | 2019-10-01 | University Of Florida Research Foundation, Incorporated | Capsid-mutated rAAV vectors and methods of use |
US8598342B2 (en) | 2008-06-12 | 2013-12-03 | President And Fellows Of Harvard College | Methods and compounds for antimicrobial intervention |
US8877242B2 (en) | 2008-07-14 | 2014-11-04 | Polypid Ltd. | Sustained-release drug carrier composition |
US10682412B2 (en) | 2008-07-14 | 2020-06-16 | Polypid Ltd. | Sustained-release drug carrier composition |
US10533998B2 (en) | 2008-07-18 | 2020-01-14 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
US11534727B2 (en) | 2008-07-18 | 2022-12-27 | Bio-Rad Laboratories, Inc. | Droplet libraries |
US11511242B2 (en) | 2008-07-18 | 2022-11-29 | Bio-Rad Laboratories, Inc. | Droplet libraries |
US11596908B2 (en) | 2008-07-18 | 2023-03-07 | Bio-Rad Laboratories, Inc. | Droplet libraries |
EP2633864A1 (en) | 2008-07-25 | 2013-09-04 | The Regents of the University of Colorado | Clip inhibitors and methods of modulating immune function |
US11898160B2 (en) | 2008-10-09 | 2024-02-13 | Minerva Biotechnologies Corporation | Method for maintaining pluripotency in cells |
EP3734281A2 (en) | 2008-11-14 | 2020-11-04 | The Brigham and Women's Hospital, Inc. | Therapeutic and diagnostic methods relating to cancer stem cells |
EP3978928A1 (en) | 2008-11-14 | 2022-04-06 | The Brigham and Women's Hospital, Inc. | Therapeutic and diagnostic methods relating to cancer stem cells |
EP3130923A1 (en) | 2008-11-14 | 2017-02-15 | The Brigham and Women's Hospital, Inc. | Therapeutic and diagnostic methods relating to cancer stem cells |
WO2010083842A2 (en) | 2009-01-23 | 2010-07-29 | Nsgene A/S | Expression of neuropeptides in mammalian cells |
US11268887B2 (en) | 2009-03-23 | 2022-03-08 | Bio-Rad Laboratories, Inc. | Manipulation of microfluidic droplets |
US8551749B2 (en) * | 2009-04-23 | 2013-10-08 | The Invention Science Fund I, Llc | Device including bone cage and method for treatment of disease in a subject |
US20100272771A1 (en) * | 2009-04-23 | 2010-10-28 | Ed Harlow | Device including bone cage and method for treatment of disease in a subject |
US8551750B2 (en) | 2009-04-23 | 2013-10-08 | The Invention Science Fund I, Llc | Device including bone cage and method for treatment of disease in a subject |
US8957075B2 (en) | 2009-06-01 | 2015-02-17 | President And Fellows Of Harvard College | O-GlcNAc transferase inhibitors and uses thereof |
EP3100723A1 (en) | 2009-06-16 | 2016-12-07 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
US8992979B2 (en) | 2009-07-14 | 2015-03-31 | Polypid Ltd. | Sustained-release drug carrier composition |
US10520500B2 (en) | 2009-10-09 | 2019-12-31 | Abdeslam El Harrak | Labelled silica-based nanomaterial with enhanced properties and uses thereof |
US10837883B2 (en) | 2009-12-23 | 2020-11-17 | Bio-Rad Laboratories, Inc. | Microfluidic systems and methods for reducing the exchange of molecules between droplets |
US9616032B2 (en) | 2010-01-19 | 2017-04-11 | Polypid Ltd. | Sustained-release nucleic acid matrix compositions |
WO2011089595A2 (en) | 2010-01-19 | 2011-07-28 | Polypid Ltd. | Sustained-release nucleic acid matrix compositions |
US8795726B2 (en) | 2010-01-19 | 2014-08-05 | Polypid Ltd. | Sustained-release nucleic acid matrix compositions |
US11390917B2 (en) | 2010-02-12 | 2022-07-19 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
US10808279B2 (en) | 2010-02-12 | 2020-10-20 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
US9074242B2 (en) | 2010-02-12 | 2015-07-07 | Raindance Technologies, Inc. | Digital analyte analysis |
US11254968B2 (en) | 2010-02-12 | 2022-02-22 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
US10351905B2 (en) | 2010-02-12 | 2019-07-16 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
US10076591B2 (en) | 2010-03-31 | 2018-09-18 | Abbott Cardiovascular Systems Inc. | Absorbable coating for implantable device |
EP3138915A1 (en) | 2010-05-04 | 2017-03-08 | The Brigham and Women's Hospital, Inc. | Detection and treatment of fibrosis |
US11635427B2 (en) | 2010-09-30 | 2023-04-25 | Bio-Rad Laboratories, Inc. | Sandwich assays in droplets |
WO2012041328A1 (en) | 2010-10-01 | 2012-04-05 | Nsgene A/S | Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain |
US10130687B2 (en) | 2011-01-05 | 2018-11-20 | Rhode Island Hospital | Compositions and methods for the treatment of orthopedic disease or injury |
US11077415B2 (en) | 2011-02-11 | 2021-08-03 | Bio-Rad Laboratories, Inc. | Methods for forming mixed droplets |
US11768198B2 (en) | 2011-02-18 | 2023-09-26 | Bio-Rad Laboratories, Inc. | Compositions and methods for molecular labeling |
US11747327B2 (en) | 2011-02-18 | 2023-09-05 | Bio-Rad Laboratories, Inc. | Compositions and methods for molecular labeling |
US11168353B2 (en) | 2011-02-18 | 2021-11-09 | Bio-Rad Laboratories, Inc. | Compositions and methods for molecular labeling |
US11754499B2 (en) | 2011-06-02 | 2023-09-12 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
WO2012174064A1 (en) | 2011-06-14 | 2012-12-20 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
WO2013013061A1 (en) | 2011-07-19 | 2013-01-24 | University Of Vermont And State Agricultural College | Methods and compounds for treating cancer |
US11898193B2 (en) | 2011-07-20 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Manipulating droplet size |
WO2013082275A1 (en) | 2011-11-30 | 2013-06-06 | Trustees Of Boston College | Inhibitors of phosphodiesterases 11 (pde11) and methods of use to elevate cortisol production |
EP2944628A1 (en) | 2011-11-30 | 2015-11-18 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
EP3936144A1 (en) | 2012-07-11 | 2022-01-12 | The University of Vermont and State Agriculture College | Methods and compositions for metabolic regulation |
US9758606B2 (en) | 2012-07-31 | 2017-09-12 | The Trustees Of Columbia University In The City Of New York | Cyclopropenium polymers and methods for making the same |
US10385150B2 (en) | 2012-07-31 | 2019-08-20 | The Trustees Of Columbia University In The City Of New York | Cyclopropenium polymers and methods for making the same |
US9119858B2 (en) | 2012-08-21 | 2015-09-01 | Genesys Research Institute, Inc. | Compositions and methods for treating or preventing anthracycline induced cardiotoxicity |
US10106778B2 (en) | 2012-11-08 | 2018-10-23 | Whitehead Institute For Biomedical Research | Selective targeting of cancer stem cells |
US11901041B2 (en) | 2013-10-04 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Digital analysis of nucleic acid modification |
US20160184234A1 (en) * | 2013-11-07 | 2016-06-30 | The General Hospital Corporation | Eluting Matrix and Uses Thereof |
US9775816B2 (en) * | 2013-11-07 | 2017-10-03 | The General Hospital Corporation | Eluting matrix and uses thereof |
US10580262B2 (en) | 2013-11-07 | 2020-03-03 | The General Hospital Corporation | Eluting matrix and uses thereof |
US9849159B2 (en) | 2013-11-07 | 2017-12-26 | The General Hospital Corporation | Eluting matrix and uses thereof |
US9849094B2 (en) * | 2013-11-07 | 2017-12-26 | The General Hospital Corporation | Eluting matrix and uses thereof |
US20160354321A1 (en) * | 2013-11-07 | 2016-12-08 | The General Hospital Corporation | Eluting Matrix and Uses Thereof |
US11174509B2 (en) | 2013-12-12 | 2021-11-16 | Bio-Rad Laboratories, Inc. | Distinguishing rare variations in a nucleic acid sequence from a sample |
US11193176B2 (en) | 2013-12-31 | 2021-12-07 | Bio-Rad Laboratories, Inc. | Method for detecting and quantifying latent retroviral RNA species |
US10398672B2 (en) | 2014-04-29 | 2019-09-03 | Whitehead Institute For Biomedical Research | Methods and compositions for targeting cancer stem cells |
US11242374B2 (en) | 2015-01-22 | 2022-02-08 | Brown University | Minimally-invasive and activity-dependent control of excitable cells |
US11897967B2 (en) | 2015-02-10 | 2024-02-13 | Minerva Biotechnologies Corporation | Humanized anti-MUC1* antibodies |
US11746159B2 (en) | 2015-02-10 | 2023-09-05 | Minerva Biotechnologies Corporation | Humanized anti-MUC1* antibodies |
WO2016134110A1 (en) | 2015-02-18 | 2016-08-25 | University Of Vermont And State Agricultural College | Mcj agonists and uses therefor |
WO2017011356A2 (en) | 2015-07-10 | 2017-01-19 | University Of Vermont And State Agricultural College | Methods and compositions to treat drug-induced diseases and conditions |
WO2017029556A1 (en) | 2015-08-20 | 2017-02-23 | Asociación Centro De Investigación Cooperativa En Biociencias - Cis Biogune | Methods and compositions to treat liver diseases and conditions |
US10647981B1 (en) | 2015-09-08 | 2020-05-12 | Bio-Rad Laboratories, Inc. | Nucleic acid library generation methods and compositions |
EP4273248A2 (en) | 2016-05-20 | 2023-11-08 | Braingene AB | Destabilising domains for conditionally stabilising a protein |
WO2017198839A1 (en) | 2016-05-20 | 2017-11-23 | Vihinen Mauno | Destabilising domains for conditionally stabilising a protein |
WO2017213695A1 (en) | 2016-06-07 | 2017-12-14 | The Brigham And Women's Hospital, Inc. | Compositions and methods relating to t peripheral helper cells in autoantibody-associated conditions |
WO2018145109A1 (en) | 2017-02-06 | 2018-08-09 | Massachusetts Institute Of Technology | Methods and products related to glutaminase inhibitors |
US11225512B2 (en) | 2017-04-27 | 2022-01-18 | University Of New Hampshire | Compositions and methods for ceramide-elevating therapeutic strategies |
WO2021168373A1 (en) | 2020-02-21 | 2021-08-26 | Mitotherapeutix Llc | Compositions and methods for inhibiting expression of methylation-controlled j-protein (mcj) |
WO2021222222A1 (en) | 2020-04-27 | 2021-11-04 | Mccray Jr Paul B | Compositions and methods for the treatment of cystic fibrosis |
WO2022233989A1 (en) | 2021-05-06 | 2022-11-10 | Hoba Therapeutics Aps | Prevention and treatment of chemotherapy-induced neuropathic pain |
WO2023104960A1 (en) | 2021-12-10 | 2023-06-15 | Hoba Therapeutics Aps | Treatment of nociceptive pain |
Also Published As
Publication number | Publication date |
---|---|
US20010051608A1 (en) | 2001-12-13 |
US20040126884A1 (en) | 2004-07-01 |
CA2190121A1 (en) | 1995-09-21 |
US6620617B2 (en) | 2003-09-16 |
US6475779B2 (en) | 2002-11-05 |
AU2121495A (en) | 1995-10-03 |
US20010020011A1 (en) | 2001-09-06 |
EP0804249A2 (en) | 1997-11-05 |
WO1995024929A3 (en) | 1995-12-28 |
US6262034B1 (en) | 2001-07-17 |
AU710504B2 (en) | 1999-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU710504B2 (en) | Polymeric gene delivery system | |
US7815941B2 (en) | Nucleic acid microspheres, production and delivery thereof | |
AU2002368202B2 (en) | Methods and compositions for therapeutic use of RNA interference | |
US6555525B2 (en) | Microencapsulation and sustained release of oligonucleotides | |
US6677313B1 (en) | Method for gene therapy using nucleic acid loaded polymeric microparticles | |
US6248720B1 (en) | Method for gene therapy using nucleic acid loaded polymeric microparticles | |
JP2007537288A (en) | Oligonucleotide-containing microspheres, use thereof for the manufacture of a medicament for treating type 1 diabetes | |
Kushibiki et al. | A new gene delivery system based on controlled release technology | |
JP2001500858A (en) | Delivery of nucleic acid particles | |
US20190216825A1 (en) | Extended-release drug delivery compositions | |
CN100384865C (en) | Methods and composition for therapeutic use of RNA interference |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2190121 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995914073 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995914073 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995914073 Country of ref document: EP |